Original Article
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
N Engl J Med 2007; 356:1809-1822May 3, 2007
- Abstract
Background
A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.
Methods
In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes.
Results
Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001).
Conclusions
A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Incidence of Fractures during the 3-Year Study Period.Article Activity
- Article
Fractures are an important cause of disability among postmenopausal women, and the costs of medical care associated with osteoporosis are estimated to be more than $18 billion annually in the United States alone.1 Bisphosphonates, the most commonly used treatment for established osteoporosis, inhibit osteoclast-mediated bone resorption and reduce the risk of vertebral fracture. Two bisphosphonates, alendronate and risedronate, also have been shown to reduce nonvertebral and hip fractures in women with osteoporosis.2-6 However, adherence to oral treatment is problematic, and about half of patients for whom oral treatment is prescribed do not adhere to it after 1 year.7,8 Poor adherence has been shown to compromise the effectiveness of treatment against fracture and to increase the costs of medical care.9,10
A single infusion of intravenous zoledronic acid has been reported to decrease bone turnover and improve bone density for at least 12 months after infusion,11 suggesting an enduring effect. In our study, annual infusions of zoledronic acid (5 mg) for 3 years were evaluated to determine whether they reduced the risk of vertebral, hip, and other types of fracture.
Methods
Study Design
The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial was an international, multicenter, randomized, double-blind, placebo-controlled trial involving postmenopausal women with osteoporosis. Patients were randomly assigned to receive either a 15-minute intravenous administration of zoledronic acid (5 mg) or placebo at baseline (day 0), at 12 months, and at 24 months. In addition, all patients received oral daily calcium (1000 to 1500 mg) and vitamin D (400 to 1200 IU). Patients were monitored for 3 years with quarterly telephone interviews and clinic visits at months 6, 12, 24, and 36.
The study was jointly designed by members of the steering committee and the sponsor. The sponsor had responsibility for data collection and quality control. An independent data and safety monitoring board met semiannually to oversee the conduct of the study and monitor the safety of patients. A copy of the study database was periodically transferred to the University of California, San Francisco (UCSF), for reports to the data and safety monitoring board. Analyses for publication were the joint responsibilities of representatives of the sponsor and investigators at UCSF. The original analyses were performed by the sponsor but were independently confirmed by investigators at UCSF. All the authors contributed to the writing of the article, and approval from a majority of the 13-member steering committee, which included 2 representatives of the sponsor, was required.
Patients
Postmenopausal women between the ages of 65 and 89 years were eligible for inclusion if they had a bone mineral density T score of −2.5 or less at the femoral neck, with or without evidence of existing vertebral fracture, or a T score of −1.5 or less, with radiologic evidence of at least two mild vertebral fractures or one moderate vertebral fracture. Previous use of oral bisphosphonates was allowed, with the duration of the washout period dependent on previous use (e.g., previous use of ≥48 weeks required 2 years of washout). Concomitant use of the following osteoporosis medications was allowed at baseline and during follow-up: hormone therapy, raloxifene, calcitonin, tibolone, tamoxifen, dehydroepiandrosterone, ipriflavone, and medroxyprogesterone. Patients were placed into one of two strata on the basis of whether they were taking osteoporosis medications at baseline. Patients in stratum 1 were not taking any osteoporosis medications at the time of randomization, whereas patients in stratum 2 were all taking an allowed medication. Patients who had previously taken bisphosphonates and met washout criteria could be randomly assigned to either stratum. Ineligibility criteria included any previous use of parathyroid hormone or sodium fluoride, use of anabolic steroids or growth hormone within 6 months before trial entry or oral or intravenous systemic corticosteroids within 12 months, and any previous use of strontium. Patients with a serum calcium level of more than 2.75 mmol per liter or less than 2.00 mmol per liter were ineligible, as were patients with a calculated creatinine clearance of less than 30.0 ml per minute at either of two baseline visits or urine dipstick results of more than 2+ for protein, without evidence of contamination or bacteriuria.
From February 2002 to June 2003, patients underwent randomization with the use of random permuted blocks within strata; the last closeout visit occurred on June 15, 2006. All patients provided written informed consent, and the local institutional review board at each center approved the protocol.
End Points
The primary end points were new vertebral fractures (in stratum 1) and hip fracture (in both strata). Secondary efficacy end points included any nonvertebral fracture, any clinical fracture, and clinical vertebral fracture. Other secondary end points were changes in bone mineral density at the total hip, femoral neck, and lumbar spine and changes in markers of bone resorption (serum C-telopeptide of type I collagen) and formation (bone-specific alkaline phosphatase and N-terminal propeptide of type I collagen). Data for premenopausal normative markers were based on 2.5th and 97.5th percentiles derived from the Os des Femmes de Lyon (OFELY) study12,13 (Delmas PD and Garnero P: personal communication). Height was measured with the use of a stadiometer, where available, at baseline and at months 12, 24, and 36.14 All investigators who performed end-point evaluations were unaware of patients' study-group assignments.
Efficacy Measurements
Spinal lateral radiographs were obtained at baseline and at 12, 24, and 36 months or early termination for patients in stratum 1 and at baseline and at 36 months or early termination for patients in stratum 2. Vertebrae from T4 to L4 were evaluated by an expert reader at a central imaging laboratory (Synarc) with the use of quantitative morphometry and standard methods.14 Incident morphometric vertebral fractures were defined as a reduction in vertebral height of at least 20% and 4 mm by quantitative morphometry, confirmed by an increase of one severity grade or more on semiquantitative analysis.14 Prevalent fracture at baseline was defined by a height ratio of at least 3 SD below the vertebra-specific mean height ratio on quantitative reading with semiquantitative confirmation.15,16
Clinical fracture reports were obtained from patients at each contact. Nonvertebral fracture reports required central confirmation, which was performed at the UCSF Coordinating Center. Evidence included either a radiologic or surgical procedure report or a copy of the radiograph. Excluded were fractures of the toe, facial bone, and finger and those caused by excessive trauma (assessed centrally as sufficient to cause fracture in a person without osteoporosis2). For clinical vertebral fractures, the community-obtained radiograph was compared with the baseline study radiograph by a central reader at Synarc, and semiquantitative confirmation was required.
Dual-energy x-ray absorptiometry of the hip was performed at baseline and at months 6, 12, 24, and 36. Investigators and coordinators were unaware of study-group assignments of patients regarding the results of follow-up scans. Bone loss was monitored centrally and if a patient's loss of bone mineral density at the total hip exceeded 8% at 1 year or 10% at 2 years, the site was notified, and the patient counseled regarding alternative treatment options. Measurements of bone mineral density at the lumbar spine were obtained for a subgroup of patients. All measurements of bone mineral density were corrected for site variations.
Levels of serum C-telopeptide of type I collagen and bone-specific alkaline phosphatase were measured in serum samples obtained after an overnight fast in a subgroup of about 600 patients from selected clinical sites. An additional cohort underwent measurement of levels of N-terminal propeptide of type I collagen from samples shipped to the central laboratory at ambient temperature. Samples obtained at all time points for each patient were analyzed in a single batch, whenever possible, at Synarc.
Adverse Events
Safety was assessed by the recording of all adverse events and serious adverse events and by physical examination, regular measurement of vital signs, and regular monitoring of hematologic, blood-chemical, and urinary values. Adverse events were categorized according to codes used in the Medical Dictionary for Regulatory Activities (MedDRA).17 The five most commonly reported symptoms that occurred within 3 days after an infusion of a study drug (post-dose symptoms) — pyrexia, influenza-like symptoms, myalgia, headache, and arthralgia — were analyzed individually and grouped.
To assess renal safety, serum creatinine was measured in a subgroup of 5035 patients 9 to 11 days after each infusion. A significant increase was defined as a rise of more than 0.5 mg per deciliter (44 μmol per liter) in the serum creatinine level, as compared with the baseline level before the first infusion. A total of 559 patients underwent 12-lead electrocardiography before and 9 to 11 days after the third infusion. Patients who were taking medications associated with QT-interval prolongation were excluded from this substudy. Adjudication or expert review was performed for several categories of adverse events, including ocular events, osteonecrosis of the jaw, hypocalcemia, renal events, incomplete fracture healing, cardiovascular events, hip and knee osteonecrosis, and death. Each adjudication committee created a set of predefined search terms on the basis of codes from MedDRA and the World Health Organization Drug Reference List. The adverse-event database was then searched for these terms. Investigators at each clinical center collected medical documentation for the cases. This documentation was forwarded to the expert panels, which performed event adjudication while members were unaware of study-group assignments. Maxillofacial events that were possibly associated with a diagnosis of osteonecrosis of the jaw were adjudicated on the basis of a definition of the disorder as the presence of exposed bone for more than 6 weeks.
Statistical Analysis
The plan for the analysis of data, which was developed before unblinding, prespecified all statistical analyses. Efficacy analyses included all patients who had undergone randomization, except for 29 patients from a site whose participation had been terminated during the study. Patients who had received at least one infusion were included in safety analyses (Figure 1Figure 1
Enrollment and Outcomes.).The incidence of vertebral fracture (stratum 1) included patients who had undergone radiography at baseline and at least once during follow-up. An incident fracture was identified if at least one follow-up radiograph met the criteria for incident fracture. Results are presented as the relative risk and 95% confidence interval (CI).
Clinical fractures (including hip fracture) were analyzed with the use of a proportional-hazards model stratified for the study stratum, with the relative hazard reported and the cumulative proportion of patients with fractures estimated by means of Kaplan–Meier analysis. Follow-up time was defined as the time from randomization to the first relevant fracture, the last study visit, or the time of death, whichever occurred first. Changes in bone mineral density were compared with the use of analysis of variance adjusted for stratum and region. Changes in biochemical markers were compared by means of analysis of covariance (ANCOVA) (loge ratio of the post-baseline value to the baseline value) adjusted for stratum, center, and baseline value. The incidence of safety events was compared with the use of Fisher's exact test.
One interim analysis of the two primary end points was conducted for the data and safety monitoring board and the final significance levels were adjusted accordingly to P=0.0496 for vertebral fracture and P=0.0406 for hip fracture. For all other tests, a P value of 0.05 or less was considered to indicate statistical significance. All reported P values are two-sided. No adjustments were made for multiple comparisons of the safety end points.
The study had a power of 90% (with a two-sided alpha of 0.05) to detect a 50% reduction in morphometric vertebral fractures in the zoledronic-acid group, assuming an annual incidence of 1.9% in the placebo group, with 2252 patients in stratum 1 (the number that was originally projected). With 7400 patients, the log-rank test had a power of 90% to detect a 50% reduction in hip fractures, assuming a 3-year fracture rate of 1.8% in the placebo group.
Results
Baseline and Follow-up
A total of 7765 women were randomly assigned to study groups: 3889 to receive zoledronic acid and 3876 to receive placebo (Figure 1). The efficacy analysis included 7736 patients (99.6%), and the safety analysis included 7714 patients (99.3%).
The mean age of patients was 73 years, with approximately half from Europe and half from North and South America and Asia (Table 1Table 1
Baseline Characteristics of the Patients.). For measures of bone mineral density at the femoral neck, 72% of the patients had T scores below −2.5, 63% had baseline vertebral fractures, and 79% were in stratum 1. Among 1652 patients in stratum 2, the number of patients who were taking raloxifene (42%) was larger than that of patients taking any other medication. A total of 6517 patients (84%) remained in active follow-up through 3 years. A total of 6260 patients (81%) received all three infusions.Fractures
The 3-year incidence of morphometric vertebral fracture was 10.9% (involving 310 women) in the placebo group versus 3.3% (92 women) in the zoledronic-acid group, a reduction of 70% (relative risk, 0.30; 95% CI, 0.24 to 0.38) (Table 2Table 2
Relative Risk of Fracture Incidence in the Two Study Groups. and Figure 2Figure 2Incidence of Fractures during the 3-Year Study Period.). Reductions were similar after 1 and 2 years (60% and 71%, respectively). The incidence of hip fracture was 2.5% (88 women) in the placebo group and 1.4% (52 women) in the zoledronic-acid group, a 41% reduction (hazard ratio, 0.59; 95% CI, 0.42 to 0.83) (Table 2 and Figure 2). As compared with the incidence in the placebo group, the incidence of secondary end points for fracture (including nonvertebral fractures, all clinical fractures, and clinical vertebral fractures) was significantly reduced in the zoledronic-acid group: by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Patients in the zoledronic-acid group had significantly less height loss (−4.2 mm) than patients in the placebo group (−7.0 mm, P<0.001).Bone Mineral Density and Biochemical Markers
In the zoledronic-acid group, bone mineral density increased significantly at the total hip (6.02%; 95% CI, 5.77 to 6.28), lumbar spine (6.71%; 95% CI, 5.69 to 7.74), and femoral neck (5.06%; 95% CI, 4.76 to 5.36), as compared with the placebo group (P<0.001 for all comparisons) (Figure 3Figure 3
Percent Change over Time in Bone Mineral Density and Biochemical Markers.). All three biochemical markers of bone turnover decreased significantly in patients in the zoledronic-acid group, as compared with those in the placebo group (Figure 3). At 12 months, levels of serum C-telopeptide of type I collagen, bone-specific alkaline phosphatase, and N-terminal propeptide of type I collagen were 59% (95% CI, 55 to 63), 30% (95% CI, 27 to 32), and 58% (95% CI, 55 to 60) lower, respectively, in the zoledronic-acid group (P<0.001 for all comparisons). At 6 and 12 months after each of the three infusions, the mean values were similar, with no progressive decline in marker values.Adverse Events
The numbers of patients who died, had a serious adverse event, or discontinued follow-up because of an adverse event did not significantly differ between the study groups (Table 3Table 3
Adverse Events.), although the number of patients with adverse events was significantly higher in the zoledronic-acid group (95.5% vs. 93.9%), primarily because of a larger number of post-dose symptoms. At 9 to 11 days after infusion, 1.3% of patients in the zoledronic-acid group had an increase of more than 0.5 mg per deciliter in the serum creatinine level, as compared with 0.4% in the placebo group. However, these changes were transient; within 30 days, the levels in more than 85% of patients had returned to within 0.5 mg per deciliter of preinfusion values, and the remainder had returned to this level by the next annual follow-up. At 3 years, there was no significant difference in either serum creatinine levels or creatinine clearance between the groups. The number of patients who had any of the five most frequently reported symptoms after the first infusion was significantly higher in the zoledronic-acid group than in the placebo group, but the number with symptoms after subsequent infusions decreased substantially. Other, less common, symptoms, including chills, nausea, bone pain, and back pain, were reported more frequently in the zoledronic-acid group. These symptoms were generally rated as mild to moderate and resolved within 3 days.The number of patients who had arrhythmia in the zoledronic-acid group (266 patients, or 6.9%) was significantly higher than that in the placebo group (203 patients, or 5.3%; P=0.003). Serious atrial fibrillation, a subcategory of all arrhythmias, was more common among patients in the zoledronic-acid group. A total of 50 patients in the zoledronic-acid group had serious atrial fibrillation (1.3%), as compared with 20 patients (0.5%) in the placebo group (P<0.001). After adjudication, the number of patients whose atrial fibrillation was reported as a serious adverse event did not change appreciably (50 in the zoledronic-acid group and 17 in the placebo group). Among the 50 patients, the events occurred more than 30 days after infusion in 47 patients. Among 559 patients who underwent electrocardiography, the prevalence of atrial fibrillation (2.1% in the zoledronic-acid group and 2.8% in the placebo group) and other electrocardiographic abnormalities did not differ significantly between the study groups. No difference was observed in the occurrence of the serious adverse events of stroke (2.3% in both study groups); the incidence of death due to stroke was 0.5% in the zoledronic-acid group and 0.3% in the placebo group (P=0.15) (Table 3).
There were no spontaneous reports of osteonecrosis of the jaw. From a search of the trial database of adverse events, which was followed by expert adjudication, two cases of potential osteonecrosis of the jaw were identified (one in the placebo group and one in the zoledronic-acid group). In both patients, delayed healing followed surgical manipulation, and both cases subsequently resolved with antibiotic therapy and débridement. A similar search for and review of osteonecrosis of the hip or knee revealed seven cases (three in the placebo group and four in the zoledronic-acid group). No adverse effect on fracture healing was observed, with three cases of nonunion (one in the placebo group and two in the zoledronic-acid group).
At 9 to 11 days after the first infusion, 49 patients in the zoledronic-acid group had a serum calcium level of less than 2.075 mmol per liter, as compared with 1 patient in the placebo group. All events were transient and asymptomatic. Patients who were treated with zoledronic acid had an absolute increase of approximately 0.69% (3.34% vs. 2.65%) in inflammatory ocular adverse events (mainly conjunctivitis) during the first 15 days after infusion.
Discussion
During a 3-year period, an annual infusion of 5 mg of zoledronic acid significantly reduced the risk of fracture at all key osteoporotic fracture sites, including the two primary end points, vertebral and hip fractures. The 70% reduction in the vertebral-fracture rate was greater than the 3-year reduction previously observed for oral bisphosphonates (40 to 50%)2,4,6,18-20 and the reductions in fracture rates associated with other antiresorptive agents.21-23 All other prospectively defined categories of fracture, including nonvertebral fractures and clinical vertebral fractures, were also significantly reduced (P<0.001 for all comparisons).
A regimen of infusions once a year appears to ensure that patients will have a full treatment effect for at least 12 months. In contrast, many patients who receive prescriptions for oral bisphosphonates stop treatment, and most appear to be taking less than 80% of their prescribed pills by 12 months.7,9,24-26 Adherence to a regimen of oral bisphosphonates is challenging because the drug must be taken with a full glass of water when the patient is fasting, and the patient must remain upright for at least 30 minutes after taking the medication. Since poor adherence reduces the antifracture efficacy,9 a single annual infusion of zoledronic acid might improve such efficacy in clinical practice.
The effect of zoledronic acid on biochemical markers in our study was similar to that reported for oral bisphosphonates.4,19,20,27-30 Furthermore, levels of bone remodeling after the second and third infusions were similar to levels after the first infusion. Taken together with the sustained decrease in fracture risk, these findings support the view that the magnitude of reduction in bone remodeling associated with zoledronic acid during a 3-year period improves bone strength without adversely affecting remodeling capacity.
As reported with other bisphosphonates that are administered intravenously, mild-to-moderate post-dose symptoms occurred most commonly after the first infusion. These symptoms typically resolved within 3 days after their onset and declined markedly with subsequent infusions. Treatment with antipyretic analgesics (e.g., ibuprofen and acetaminophen) appeared to mitigate these symptoms.
The study protocol included monitoring for adverse renal effects 9 to 11 days after each infusion in more than 5000 patients; only small and transient increases in serum creatinine levels were observed. At 3 years, there was no systematic deterioration in estimated creatinine clearance.
There was a small increase in the risk of inflammatory ocular adverse events within the first 15 days after infusion, as reported with other bisphosphonates.31 All such events were treated and resolved with outpatient treatment.
Most cases of osteonecrosis of the jaw have been observed in patients with cancer who were treated with frequent doses of intravenous bisphosphonates.32-35 Our study assessed the incidence of osteonecrosis of the jaw prospectively in a large number of women with osteoporosis who were receiving a bisphosphonate. There were no spontaneous reports of osteonecrosis of the jaw by patients in our study. In addition, blinded adjudication of the safety database yielded one case in the zoledronic-acid group and one in the placebo group, suggesting that the risk of osteonecrosis of the jaw in women with postmenopausal osteoporosis is very low and that this disorder may occur without bisphosphonate treatment. A once-yearly regimen with intravenous zoledronic acid does not appear to affect the frequency of this adverse event.
An increased incidence of serious atrial fibrillation was observed in the zoledronic-acid group, as compared with the placebo group. The events were uniformly distributed over time, with the vast majority of events occurring more than 30 days after infusion, by which time zoledronic acid is undetectable in the circulation. There are no studies establishing biologic mechanisms that might link bisphosphonate therapy to atrial fibrillation or arrhythmia. Alterations in serum calcium levels could be related to atrial fibrillation, but the administration of zoledronic acid had little or no effect on serum calcium levels measured 9 to 11 days after infusion. Electrocardiography that was performed before and 9 to 11 days after the third infusion in 559 patients who were not taking drugs that cause prolongation of QT intervals showed no significant difference between groups in the prevalence of arrhythmia. However, low-frequency, intermittent arrhythmia might not have been captured on the short echocardiogram in this subgroup. An increased risk of serious atrial fibrillation had not been previously associated with zoledronic acid or other bisphosphonates, although a letter in this issue of the Journal 36 reports a similar, though nonsignificant, trend from the 1997 Fracture Intervention Trial of alendronate. The observed association might be due to chance but should be further explored in other trials of zoledronic acid and reanalyses of data from other bisphosphonate trials.
In conclusion, a once-yearly infusion of zoledronic acid during a 3-year period was associated with a significant and sustained decrease in the risk of vertebral, hip, and other fractures. In addition, the treatment had a favorable safety profile and was generally well tolerated. Given the relatively poor adherence to oral bisphosphonate therapy in clinical practice, annual infusion of zoledronic acid may provide a promising approach to reducing fracture risk.
Supported by Novartis Pharma.
Dr. Black reports receiving grant support and honoraria from Novartis and Merck; Dr. Delmas, consulting, advisory board, or lecture fees, or any combination of the three, from Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Procter & Gamble, Sanofi-Aventis, Servier, and Wyeth; Dr. Eastell, consulting or advisory board fees from Amgen, AstraZeneca, Aventis, California Pacific Medical Center, GlaxoSmithKline, Hologic, Kyphon, Lilly Industries, Maxygen, Nastech Pharmaceuticals, Nestle Research Center, New Zealand Milk Limited, Novartis, Novo-Nordisk, Ono Pharma, Organon Laboratories, Osteologix, Pfizer, Procter & Gamble Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Servier, Shire, Transpharma Medical Limited, Unilever, and Unipath; having equity ownership or stock options in Interleukin Genetics; receiving lecture fees from Aventis, Aventis Pharmaceuticals, Lilly, Procter & Gamble Pharmaceuticals, Novartis, and Pfizer; and receiving grant support from Amgen, Arthritis Research Campaign, AstraZeneca, Aventis, California Pacific Medical Center Research Institute, Cavendish Hip Foundation, Eli Lilly Medical Research Council, Interleukin Genetics, Novartis, Novartis Pharmaceuticals UK, Novo Nordisk, Organon Laboratories, Parexel International, Pfizer, Procter & Gamble Pharmaceuticals, Sanofi-Aventis, Sheffield Teaching Hospitals Foundation Trust, Unipath, and the University of Kiel; Dr. Reid, consulting or advisory board fees from Amgen, Novartis, Merck, and Sanofi-Aventis; lecture fees from Fonterra, Merck, Novartis, and Sanofi-Aventis; and grant support from Amgen, Merck, Health Research Council of New Zealand, and Novartis; Dr. Boonen, consulting or advisory board fees from Eli Lilly, Merck, Novartis, Procter & Gamble, Sanofi-Aventis, and Servier; lecture fees from Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, Sanofi-Aventis, and Servier; and grant support from Amgen, Eli Lilly, Novartis, Pfizer, Procter & Gamble, Sanofi-Aventis, and Roche–GlaxoSmithKline; Dr. Cauley, consulting or advisory board fees from Lilly and Novartis, lecture fees from Merck, and grant support from Boston University, Cal Pac Medical Center, Lilly, Merck, National Institutes of Health, Novartis, Pfizer, University of California–Davis, University of California–Los Angeles, and the University of Arizona; Dr. Cosman, consulting or advisory board fees from Eli Lilly, Merck, Novartis, NPS Pharmaceuticals, Procter & Gamble, and Pfizer and lecture fees from Eli Lilly, Merck, and Roche; Dr. Man, consulting fees or advisory board fees from Novartis and lecture fees from Aventis and Roche; Dr. Mautalen, consulting or advisory board fees from Novartis and Roche and lecture fees from Roche; Dr. Mesenbrink, Dr. Hu, and Ms. Tong, being employees of Novartis; Drs. Caminis (now employed by NPS Pharmaceuticals), Rosario-Janssen (now employed by Savient Pharmaceuticals), and Krasnow (now employed by Roche Pharma), being employees of Novartis during the study; Dr. Rosario-Jansen, owning stock in Novartis; Ms. Hue, consulting fees from NPS Pharmaceuticals; Dr. Sellmeyer, lecture fees from Merck and grant support from Amgen, the National Institutes of Health, the Dairy Council of California, and the California Dietetic Association; Dr. Eriksen, being an employee of Novartis; Dr. Cummings, consulting or advisory board fees and grant support from Amgen, Eli Lilly, Pfizer, and Novartis and lecture fees from Merck and Eli Lilly. No other potential conflict of interest relevant to this article was reported.
We thank Zeb Horowitz (now employed at Savient Pharmaceuticals) and John Orloff (at Novartis).
Source Information
From the University of California, San Francisco, San Francisco (D.M.B., T.F.H., D.S.); Université Claude Bernard Lyon 1 and INSERM Research Unit 831, Lyon, France (P.D.D.); University of Sheffield, Sheffield, United Kingdom (R.E.); University of Auckland, Auckland, New Zealand (I.R.R.); Katholieke Universiteit Leuven, Leuven, Belgium (S.B.); University of Pittsburgh, Pittsburgh (J.A.C.); Helen Hayes Hospital, West Haverstraw, NY (F.C.); Semmelweis University Medical School, Budapest, Hungary (P.L.); the Chinese University of Hong Kong, Hong Kong (P.C.L.); Centro Tratamiento Integral Endocrinología Metabolismo Patología Ósea, Buenos Aires (Z.M.); Centro de Osteopatías Médicas, Buenos Aires (C.M.); Novartis Pharmaceuticals, East Hanover, NJ (P.M., H.H., J.C., K.T., T.R.-J., J.K.); Novartis Pharma, Basel, Switzerland (E.F.E.); and San Francisco Coordinating Center, San Francisco (S.R.C.).
Address reprint requests to Dr. Black at the Department of Epidemiology and Biostatistics, University of California, San Francisco, 185 Berry St., Lobby 4, Suite 5700, San Francisco, CA 94107, or at dblack@psg.ucsf.edu.
Investigators for the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial are listed in the Appendix.
Appendix
The following investigators participated in the HORIZON-PFT study: Steering Committee — D. Black (chair), S. Cummings, P. Delmas, R. Eastell, I. Reid, S. Boonen, J. Cauley, F. Cosman, P. Lakatos, P.C. Leung, Z. Man, E.F. Eriksen (Novartis), P. Mesenbrink (Novartis); Past Steering Committee — E. Lau, S. Jasqui, C. Mautalen, T. Rosario-Jansen (Novartis), J. Caminis (Novartis); Data and Safety Monitoring Board (DSMB) — L. Raisz (chairman), P. Bauer, J. Compston, D. DeMets, R. Hirschberg, O. Johnell, S. Ralston, R. Wallace; DSMB Consultants — M. Farkough; Novartis — M. Flood; University of California, San Francisco (UCSF) Coordinating Center — D. Bauer, L. Palermo; UCSF Radiology (QCT analysis) — T. Lang. The following investigators are listed according to clinical site — Argentina: E. Kerzberg, Z. Man, C. Mautalen, M. Ridruejo, G. Tate, J. Velasco; Australia: M. Hooper, M. Kotowicz, P. Nash, R. Prince, A. Roberts, P. Sambrook; Austria: H. Dobnig, G. Finkenstedt, G. Hoefle, K. Klaushofer, M. Pecherstorfer, P. Peichl; Belgium: J. Body, S. Boonen, J.-P. Devogelaer, P. Geusens, J. Kaufman; Brazil: J. Brenol, J. Kochen, R. Lederman, S. Radominski, V. Szejnfeld, C. Zerbini; Canada: J. Adachi, J. Brown, D. Choquette, D. Hanley, R. Josse, D. Kendler, R. Kremer, F. Morin, W. Olszynski, A. Papaioannou, C.K. Yuen; China: B. Chen, S. Lin; Colombia: N. Casas, M. Chalem, J. Jaller, J. Molina; Finland: H. Aro, J. Heikkinen, H. Kröger, L. Mäkinen, J. Saltevo, J. Salmi, M. Välimäki; France: C.-L. Benhamou, P. Delmas, P. Fardellone, G. Werhya; Germany: B. Allolio, D. Felsenberg, J. Happ, M. Hartard, J. Hensen, P. Kaps, J. Kekow, R. Moericke, B. Ortloff, P. Schneider, S. Wassenberg; Hong Kong: P.C. Leung; Hungary: A. Balogh, B. Gomor, T. Hidvégi, L. Koranyi, P. Lakatos, G. Poór, Z. Tulassay; Israel: R.D. Pollak, V. Eshed, A.J. Foldes, S. Ish-Shalom, I. Vered, M. Weiss; Italy: S. Adami, A. Barone, G. Bianchi, S. Giannini, G.C. Isaia, G. Luisetto, S. Minisola, N. Molea, R. Nuti, S. Ortolani, M. Passeri, A. Rubinacci, B. Seriolo, L. Sinigaglia; Republic of Korea: W.-H. Choi, M.-I. Kang, G.-S. Kim, H.-S. Kim, Y.-K. Kim, S.-K. Lim, H.-Y. Son, H.-K. Yoon; Mexico: C. Abud, P. Garcia, S. Jasqui, L. Ochoa, J. Orozco, J. Santos; New Zealand: I. Reid; Norway: S. Elle, J. Halse, A. Høiseth, H. Olav, H.I. Røed, A. Skag, J. Stakkestad, U. Syversen; Poland: J. Badurski, E. Czerwinski, R. Lorenc, E. Marcinowska-Suchowierska, A. Sawicki, J. Supronik; Russia: E. Ailamazyan, L. Benevolenskaya, A. Dreval, L. Dvoretsky, R. Dyomina, V. Mazurov, G. Melnichenko, A. Mkrtoumyan, A. Orlov-Morozov, O. Ostroumova, E. Pikhlak, T. Shemerovskaya, N. Shostak, I. Skripnikova, V. Smetnik, E. Tsyrlina, G. Usova, A. Zalevskaya, I. Zazerskaya, E. Zotkin; Sweden: O. Ljunggren, J. Lofgren, M. Palmér, M. Saaf, M. Stenström; Switzerland: P. Hasler, O. Lamy, K. Lippuner, C. Merlin, R. Rizzoli, R. Theiler, A. Tyndall, D. Uebelhart; Taiwan: J.-F. Chen, P.-Q. Chen, L.-S. Chin, J.-S. Hwang, T.-S. Yang, M. Jirapinyo; Thailand: M. Jirapinyo, R. Sattaya, S. Sriussadaporn, S. Supasin, N. Taechakraichana, K. Wilawan; United Kingdom: H. Donnachie, R. Eastell, W. Fraser, A. McLellan, D. Reid; United States: J. Abruzzo, R. Ackerman, R. Adler, J. Aloia, C. Birbara, B. Bode, H. Bone, D. Brandon, J. Cauley, F. Cosman, D. Dionne, R. Downs, Jr., J. Dreyfus, V. Elinoff, R. Emkey, J. Fanciullo, D. Fiske, P. Genaro, M. Gollapudi, R. Gordon, J. Hennessey, P. Howard, K. Johnson, C. Johnston, R. Kagan, S. Kafka, J. Kaine, T. Klein, W. Koltun, M. Leboff, B. Levine, E.M. Lewiecki, C.E. Lewis, A. Licata, M. Lillestol, B. Lubin, R. Malamet, A. Mangione, V. Matkovic, D. Mehta, P. Miller, S. Miller, F.T. Murphy, S. Nattrass, D. Podlecki, C. Recknor, C. Rosen, D. Rowe, R. Rude, T. Schnitzer, Y. Sherrer, S. Silverman, K. Stephenson, B. Troupin, J. Tucci, R. Villareal, N. Watts, R. Weinstein, R. Weinstein, M. Weitz, R. White.
- References
References
1
Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Office of the Surgeon General, 2004.
2
Black DM ,Cummings SR ,Karpf DB , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541
CrossRef | Web of Science | Medline3
Cummings SR ,Black DM ,Thompson DE , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082
CrossRef | Web of Science | Medline4
Harris ST ,Watts NB ,Genant HK , et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-1352
CrossRef | Web of Science | Medline5
McClung MR ,Geusens P ,Miller PD , et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340
Full Text | Web of Science | Medline6
Reginster J ,Minne HW ,Sorensen OH , et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
CrossRef | Web of Science | Medline7
Cramer JA ,Amonkar MM ,Hebborn A ,Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460
CrossRef | Web of Science | Medline8
Lo JC ,Pressman AR ,Omar MA ,Ettinger B . Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-928
CrossRef | Web of Science | Medline9
Siris ES ,Harris ST ,Rosen CJ , et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022
CrossRef | Web of Science | Medline10
Huybrechts KF ,Ishak KJ ,Caro JJ . Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-928
CrossRef | Web of Science | Medline11
Reid IR ,Brown JP ,Burckhardt P , et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661
Full Text | Web of Science | Medline12
Garnero P ,Sornay-Rendu E ,Claustrat B ,Delmas PD . Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-1536
CrossRef | Web of Science | Medline13
Garnero P ,Sornay-Rendu E ,Chapuy MC ,Delmas PD . Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-349
CrossRef | Web of Science | Medline14
Black DM ,Palermo L ,Nevitt MC ,Genant HK ,Christensen L ,Cummings SR . Defining incident vertebral deformity: a prospective comparison of several approaches. J Bone Miner Res 1999;14:90-101
CrossRef | Web of Science | Medline15
Black DM ,Palermo L ,Nevitt MC , et al. Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res 1995;10:890-902
CrossRef | Web of Science | Medline16
Genant HK ,Wu CY ,van Kuijk C ,Nevitt MC . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148
CrossRef | Web of Science | Medline17
Medical dictionary for regulatory activities (MedDRA). Reston, VA: Northrup Grumman, 2003.
18
Chesnut CH III ,Skag A ,Christiansen C , et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249
CrossRef | Web of Science | Medline19
Miller PD ,McClung MR ,Macovei L , et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322
CrossRef | Web of Science | Medline20
Reginster JY ,Adami S ,Lakatos P , et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661
CrossRef | Web of Science | Medline21
Chesnut CH III ,Silverman S ,Andriano K , et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;109:267-276
CrossRef | Web of Science | Medline22
Ettinger B ,Black DM ,Mitlak BH , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645[Erratum, JAMA 1999;282:2124.]
CrossRef | Web of Science | Medline23
Siris E ,Adachi JD ,Lu Y , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Osteoporos Int 2002;13:907-913
CrossRef | Web of Science | Medline24
Cooper AL. Improved patient persistence on once-monthly dosing regime plus patient support compared with a weekly dosing regime. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis, Toronto, June 2–6, 2006 (poster).
25
Downey TW ,Foltz SH ,Boccuzzi SJ ,Omar MA ,Kahler KH . Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006;99:570-575
CrossRef | Web of Science | Medline26
Recker RR ,Gallagher R ,MacCosbe PE . Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-861
CrossRef | Web of Science | Medline27
Black DM ,Bilezikian JP ,Ensrud KE , et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-565
Full Text | Web of Science | Medline28
Bonnick S ,Saag KG ,Kiel DP , et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631-2637
CrossRef | Web of Science | Medline29
Sebba AI ,Bonnick SL ,Kagan R , et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2004;20:2031-2041[Erratum, Curr Med Res Opin 2005;21:325.]
CrossRef | Web of Science | Medline30
Delmas PD ,Recker RR ,Chesnut CH III , et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-798
CrossRef | Web of Science | Medline31
Fraunfelder FW ,Fraunfelder FT . Bisphosphonates and ocular inflammation. N Engl J Med 2003;348:1187-1188
Full Text | Web of Science | Medline32
Woo SB ,Hellstein JW ,Kalmar JR . Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761[Erratum, Ann Intern Med 2006;145:235.]
Web of Science | Medline33
Hoff AO ,Toth BB ,Altundag K , et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:Suppl 18:8528-852834
Ruggiero SL ,Mehrotra B ,Rosenberg TJ ,Engroff SL . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
CrossRef | Web of Science | Medline35
Ruggiero S ,Gralow J ,Marx RE , et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14
CrossRef36
Cummings S ,Schwartz A ,Black DM . Atrial fibrillation and alendronate. N Engl J Med 2007;356:1895-1896
Full Text | Web of Science | Medline
- Citing Articles (528)
Citing Articles
1
Shunji Takahashi, Takuji Iwase, Norio Kohno, Takashi Ishikawa, Tetsuya Taguchi, Masato Takahashi, Jun Horiguchi, Seigo Nakamura, Yasuo Hozumi, Masao Fukunaga, Shinzaburo Noguchi. (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Research and Treatment
CrossRef2
Robert A. Adler. (2012) Secondary Fracture Prevention. Current Osteoporosis Reports
CrossRef3
Chao Li, Hui-Ren Wang, Xi-Lei Li, Xiao-Gang Zhou, Jian Dong. (2012) The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochirurgica
CrossRef4
Juliet Compston. (2012) The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41:1, 11-18
CrossRef5
J. D. Wark, W. Bensen, C. Recknor, O. Ryabitseva, J. Chiodo, P. Mesenbrink, T. J. Villiers. (2012) Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporosis International 23:2, 503-512
CrossRef6
P. Hadji, D. Gamerdinger, W. Spieler, P. H. Kann, H. Loeffler, K. Articus, R. Möricke, V. Ziller. (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporosis International 23:2, 625-633
CrossRef7
Sarah G. Fitzpatrick, Mary F. Stavropoulos, Leah M. Bowers, Ashley N. Neuman, David W. Hinkson, James G. Green, Indraneel Bhattacharyya, Donald M. Cohen. (2012) Bisphosphonate-Related Osteonecrosis of Jaws in 3 Osteoporotic Patients With History of Oral Bisphosphonate Use Treated With Single Yearly Zoledronic Acid Infusion. Journal of Oral and Maxillofacial Surgery 70:2, 325-330
CrossRef8
Rozalia Dimitriou, Giorgio Maria Calori, Peter V Giannoudis. (2012) Improving patients’ outcomes after osteoporotic fractures. International Journal of Clinical Rheumatology 7:1, 109-124
CrossRef9
J.-J. Body, P. Bergmann, S. Boonen, J.-P. Devogelaer, E. Gielen, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster. (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis International 23:S1, 1-23
CrossRef10
A. S. Carmel, A. Shieh, H. Bang, R. S. Bockman. (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporosis International
CrossRef11
S. Silverman, C. Christiansen. (2012) Individualizing osteoporosis therapy. Osteoporosis International
CrossRef12
Tingting Yan, Wenjin Yin, Qiong Zhou, Liheng Zhou, Yiwei Jiang, Yueyao Du, Zhimin Shao, Jinsong Lu. (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. European Journal of Cancer 48:2, 187-195
CrossRef13
M. S. Cooper, A. J. Palmer, M. J. Seibel. (2012) Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study. Osteoporosis International 23:1, 97-107
CrossRef14
Mary K. Beard. (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Current Medical Research and Opinion 28:1, 141-147
CrossRef15
E. Barrett-Connor, A. S. Swern, C. M. Hustad, H. G. Bone, U. A. Liberman, S. Papapoulos, H. Wang, A. Papp, A. C. Santora. (2012) Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporosis International 23:1, 233-245
CrossRef16
Ming Zhao, Yohei Tominaga, Kenoki Ohuchida, Kazuhiro Mizumoto, Lin Cui, Shingo Kozono, Hayato Fujita, Ryo Maeyama, Hiroki Toma, Masao Tanaka. (2012) Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Science 103:1, 58-66
CrossRef17
JH Krege, X Wan. (2012) Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone 50:1, 161-164
CrossRef18
R. Wustrack, E. Seeman, C. Bucci-Rechtweg, S. Burch, L. Palermo, D. M. Black. (2012) Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporosis International 23:1, 53-58
CrossRef19
Ryan C. Outman, Jeffrey R. Curtis, Julie L. Locher, Jeroan J. Allison, Kenneth G. Saag, Meredith L. Kilgore. (2012) Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. Contemporary Clinical Trials 33:1, 206-212
CrossRef20
Terry J. Aspray, Roger M. Francis. (2012) Treatment of osteoporosis in women intolerant of oral bisphosphonates. Maturitas 71:1, 76-78
CrossRef21
J. A. Kanis, J.-Y. Reginster, J.-M. Kaufman, J.-D. Ringe, J. D. Adachi, M. Hiligsmann, R. Rizzoli, C. Cooper. (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International 23:1, 213-221
CrossRef22
C. W. Rhee, J. Lee, S. Oh, N. K. Choi, B. J. Park. (2012) Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporosis International 23:1, 247-254
CrossRef23
E. Michael Lewiecki, John P. Bilezikian, Lawrence G. Jankowski, Eugene V. McCloskey, Paul D. Miller, Sarah L. Morgan, Eric S. Orwoll, John T. Potts. (2012) Proceedings of the 2011 Santa Fe Bone Symposium. Journal of Clinical Densitometry 15:1, 1-20
CrossRef24
Sophie A. Jamal, Celeste J. Hamilton. (2011) Nitric Oxide Donors for the Treatment of Osteoporosis. Current Osteoporosis Reports
CrossRef25
Hai NIE, Chao PENG, Jie HAO, Zhen-ming HU, Hong AN. (2011) Zoledronic acid in preventing fractures in women with postmenopausal osteoporosis: a meta analysis. Academic Journal of Second Military Medical University 31:9, 985-990
CrossRef26
Celeste J. Hamilton, Sophie A. Jamal, Earl R. Bogoch. 2011. Osteoporosis and Metabolic Disorders. , 35-55.
CrossRef27
Charles S. Haworth, Linda Sharples, Vikki Hughes, Sarah L. Elkin, Margaret E. Hodson, Steven P. Conway, Christine Etherington, J. Stuart Elborn, Jackie Rendall, Ella Wheaton, Emma Kadri, Jane Elliott, Helen C. Barker, Philip W.P. Bearcroft, Thinn Hlaing, Juliet E. Compston. (2011) Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. Journal of Cystic Fibrosis 10:6, 470-476
CrossRef28
Zhanna E. Belaya. (2011) Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG. Rheumatology International 31:12, 1669-1671
CrossRef29
Devin L. Stewart. (2011) Prosthodontic treatment of a patient taking nitrogen-containing bisphosphonates to preserve the integrity of the epithelial attachment: A clinical report. The Journal of Prosthetic Dentistry 106:6, 350-354
CrossRef30
Eetu Heervä, Sirkku Peltonen, Erkki Svedström, Hannu T. Aro, Kalervo Väänänen, Juha Peltonen. (2011) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone
CrossRef31
Yasuo Ochi, Hiroyuki Yamada, Hiroshi Mori, Yasutomo Nakanishi, Satoshi Nishikawa, Ryoji Kayasuga, Naoki Kawada, Akiko Kunishige, Yasuaki Hashimoto, Makoto Tanaka, Masafumi Sugitani, Kazuhito Kawabata. (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49:6, 1351-1356
CrossRef32
Maurice Audran, Bernard Cortet, Thierry Thomas. (2011) What do we know about atypical femoral fractures? Insights and enigmas. Joint Bone Spine 78:6, 568-571
CrossRef33
M. Gosch, T. Roth, C. Kammerlander, B. Joosten-Gstrein, U. Benvenuti-Falger, M. Blauth, M. Lechleitner. (2011) Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation. Zeitschrift für Gerontologie und Geriatrie 44:6, 381-386
CrossRef34
M. Manara. (2011) Le terapie farmacologiche nelle fratture da fragilità. Archivio di Ortopedia e Reumatologia 122:3-4, 20-21
CrossRef35
Thomas P. Olenginski, Jana L. Antohe, Elaine Sunderlin, Thomas M. Harrington. (2011) Appraising osteoporosis care gaps. Rheumatology International
CrossRef36
Robin K. Dore. (2011) Data from Extension Trials: Denosumab and Zoledronic Acid. Current Osteoporosis Reports
CrossRef37
P. Hadji, V. Ziller, D. Gamerdinger, W. Spieler, K. Articus, M. Baier, R. Moericke, P. H. Kann. (2011) Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporosis International
CrossRef38
Lluís Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria, Estíbaliz Loza. (2011) Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. Reumatología Clínica 7:6, 357-379
CrossRef39
Peyman Hadji. (2011) Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Critical Reviews in Oncology/Hematology 80:2, 301-313
CrossRef40
Lluis Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i. Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria, Estíbaliz Loza. (2011) 2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis. Reumatolog ía Cl ínica (English Edition) 7:6, 357-379
CrossRef41
Marie-Paule Lecart, Jean-Yves Reginster. (2011) Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy 12:16, 2533-2552
CrossRef42
Kerri Durnell Schuiling, Kristi Robinia, Rachel Nye. (2011) Osteoporosis Update. Journal of Midwifery & Women's Health 56:6, 615-627
CrossRef43
Kurt Lippuner, Richard F. Pollock, Jayne Smith-Palmer, Thomas Meury, William J. Valentine. (2011) A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 9:6, 403-417
CrossRef44
Steven Boonen, Eric Orwoll, Jay Magaziner, Cathleen S. Colón-Emeric, Jonathan D. Adachi, Christina Bucci-Rechtweg, Patrick Haentjens, Jean-Marc Kaufman, Rene Rizzoli, Dirk Vanderschueren, Frank Claessens, An Sermon, Richard Witvrouw, Koen Milisen, Guoqin Su, Kenneth W. Lyles, . (2011) Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture. Journal of the American Geriatrics Society 59:11, 2084-2090
CrossRef45
K Henriksen, DJ Leeming, C Christiansen, MA Karsdal. (2011) Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options. Women's Health 7:6, 689-698
CrossRef46
Pongthorn Narongroeknawin, Nivedita M. Patkar, Bita Shakoory, Archana Jain, Jeffrey R. Curtis, Elizabeth Delzell, Philip H. Lander, Robert R. Lopez-Ben, Michael J. Pitt, Monika M. Safford, David A. Volgas, Kenneth G. Saag. (2011) Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data. Journal of Clinical Densitometry
CrossRef47
Dulcinea Candelaria-Quintana, Zoneddy R. Dayao, Melanie E. Royce. (2011) The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer. Breast Cancer Research and Treatment
CrossRef48
C. Roux, D. M. Reid, J.-P. Devogelaer, K. Saag, C. S. Lau, J.-Y. Reginster, P. Papanastasiou, C. Bucci-Rechtweg, G. Su, P. N. Sambrook. (2011) Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporosis International
CrossRef49
Maurice Audran, Bernard Cortet, Thierry Thomas. (2011) Que sait-on des fractures fémorales atypiques ? Entre progrès et inconnues. Revue du Rhumatisme 78:5, 423-426
CrossRef50
Yuji Doi, Masashi Miyazaki, Toyomi Yoshiiwa, Katsutoshi Hara, Masashi Kataoka, Hiroshi Tsumura. (2011) Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model. Bone 49:4, 777-782
CrossRef51
Mickaël Rousière. (2011) De l’importance de prendre en charge l’ostéoporose. La Presse Médicale 40:10, 900-909
CrossRef52
Pasi Pulkkinen, Claus - C. Glüer, Timo Jämsä. (2011) Investigation of differences between hip fracture types: A worthy strategy for improved risk assessment and fracture prevention. Bone 49:4, 600-604
CrossRef53
Sydney Lou Bonnick. (2011) Going on a Drug Holiday?. Journal of Clinical Densitometry 14:4, 377-383
CrossRef54
Dawn C Mackey, Dennis M Black, Douglas C Bauer, Eugene V McCloskey, Richard Eastell, Peter Mesenbrink, John R Thompson, Steven R Cummings. (2011) Effects of antiresorptive treatment on nonvertebral fracture outcomes. Journal of Bone and Mineral Research 26:10, 2411-2418
CrossRef55
R Erichsen, C F Christiansen, T Frøslev, J Jacobsen, H T Sørensen. (2011) Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. British Journal of Cancer 105:7, 881-883
CrossRef56
E. Michael Lewiecki. (2011) New targets for intervention in the treatment of postmenopausal osteoporosis. Nature Reviews Rheumatology 7:11, 631-638
CrossRef57
Jian Sheng Chen, Philip N. Sambrook. (2011) Antiresorptive therapies for osteoporosis: a clinical overview. Nature Reviews Endocrinology
CrossRef58
Y. F. Li, C. C. Zhou, J. H. Li, E. Luo, S. S. Zhu, G. Feng, J. Hu. (2011) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporosis International
CrossRef59
P. N. Sambrook, I. D. Cameron, J. S. Chen, L. M. March, J. M. Simpson, R. G. Cumming, M. J. Seibel. (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporosis International 22:9, 2551-2556
CrossRef60
Pei-Yu Lu, Chi-Feng Hsieh, Yi-Wen Tsai, Weng-Foung Huang. (2011) Alendronate and Raloxifene Use Related to Cardiovascular Diseases: Differentiation by Different Dosing Regimens of Alendronate. Clinical Therapeutics 33:9, 1173-1179
CrossRef61
K. Lippuner, A. W. Popp, P. Schwab, M. Gitlin, T. Schaufler, C. Senn, R. Perrelet. (2011) Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporosis International 22:9, 2487-2497
CrossRef62
Jacques P. Brown, J.D. Adachi, D.L. Kendler, R. Rigal, G. Deutsch, J.M. Leclerc. (2011) A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial. Contemporary Clinical Trials 32:5, 741-746
CrossRef63
Brian J Rebolledo, Aasis Unnanuntana, Joseph M Lane. (2011) A Comprehensive Approach to Fragility Fractures. Journal of Orthopaedic Trauma 25:9, 566-573
CrossRef64
Susan M Ott, Tilman B Drueke, Sharon M Moe. (2011) The Authors Reply:. Kidney International 80:5, 554-554
CrossRef65
E. Michael Lewiecki. (2011) The Role of Risk Communication in the Care of Osteoporosis. Current Osteoporosis Reports 9:3, 141-148
CrossRef66
James J. Zahrowski. (2011) Optimisation des traitements orthodontiques chez les patients sous biphosphonates. L'Orthodontie Française 82:3, 279-298
CrossRef67
Glen M. Blake, Musib Siddique, Michelle L. Frost, Amelia E.B. Moore, Ignac Fogelman. (2011) Radionuclide studies of bone metabolism: Do bone uptake and bone plasma clearance provide equivalent measurements of bone turnover?. Bone 49:3, 537-542
CrossRef68
Ronald C. Hamdy, Dustin M. Price, Miriam M. Mottl. (2011) Diagnostic Thresholds in Osteoporosis: How Are They Used in Clinical Trials?. Current Osteoporosis Reports 9:3, 160-166
CrossRef69
Ove Törring. (2011) Denosumab for treatment of osteoporosis in postmenopausal women. Clinical Investigation 1:9, 1329-1340
CrossRef70
René Rizzoli, Jean-Yves Reginster. (2011) Adverse drug reactions to osteoporosis treatments. Expert Review of Clinical Pharmacology 4:5, 593-604
CrossRef71
Daniele Diacinti, Daniela Pisani, Romano Del Fiacco, Cristiano Maria Francucci, Carmelo Erio Fiore, Bruno Frediani, Antonella Barone, Tommaso Bartalena, Maria Sofia Cattaruzza, Giuseppe Guglielmi, Davide Diacinti, Elisabetta Romagnoli, Salvatore Minisola. (2011) Vertebral morphometry by X-ray absorptiometry: Which reference data for vertebral heights?. Bone 49:3, 526-536
CrossRef72
Ian R. Reid. (2011) Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiology 40:9, 1191-1196
CrossRef73
Leon A. Assael. (2011) Bisphosphonates and Oral Health: Primer and an Update for the Practicing Surgeon. Oral and Maxillofacial Surgery Clinics of North America 23:3, 443-453
CrossRef74
Péter Lakatos. (2011) Az osteoporosis gyógyszeres kezelése – 2011. Orvosi Hetilap 152:33, 1320-1326
CrossRef75
René Rizzoli, Jean-Yves Reginster, Steven Boonen, Gérard Bréart, Adolfo Diez-Perez, Dieter Felsenberg, Jean-Marc Kaufman, John A. Kanis, Cyrus Cooper. (2011) Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International 89:2, 91-104
CrossRef76
Andrew J. Laster, S. Bobo Tanner. (2011) Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?. Rheumatic Disease Clinics of North America 37:3, 323-336
CrossRef77
Mohammad Kharazmi, Kerstin Sjöqvist, Gunnar Warfvinge. (2011) Oral Ulcers, a Little Known Adverse Effect of Alendronate: Review of the Literature. Journal of Oral and Maxillofacial Surgery
CrossRef78
Slobodan Vukicevic, Lovorka Grgurević. (2011) The PEARL trial: lasofoxifene and incidence of fractures, breast cancer and cardiovascular events in postmenopausal osteoporotic women. International Journal of Clinical Rheumatology 6:4, 387-391
CrossRef79
S. L. Silverman, A. Kriegman, J. Goncalves, F. Kianifard, T. Carlson, E. Leary. (2011) Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporosis International 22:8, 2337-2345
CrossRef80
Roger H Jay, Sarah L Marrinan. (2011) Osteoporosis treatment and the older patient. Reviews in Clinical Gerontology 21:03, 233-245
CrossRef81
Peyman Hadji, Michael Gnant, Matti Aapro, Allan Lipton, Robert Coleman. (2011) Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Critical Reviews in Oncology/Hematology 79:2, 175-188
CrossRef82
Julie LI-YU, Emmanuel C. PEREZ, Arturo CAÑETE, Lauro BONIFACIO, Lyndon Q. LLAMADO, Romil MARTINEZ, Allan LANZON, Mae SISON, . (2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. International Journal of Rheumatic Diseases 14:3, 223-238
CrossRef83
Jean-Pierre Devogelaer, Yves Boutsen, Damien Gruson, Daniel Manicourt. (2011) Is There a Place for Bone Turnover Markers in the Assessment of Osteoporosis and its Treatment?. Rheumatic Disease Clinics of North America 37:3, 365-386
CrossRef84
Steven R. Goldstein. (2011) Bone health medications. Menopause 18:8, 835-836
CrossRef85
Gloria Bachmann, Audrey Kriegman, Joana Gonçalves, Farid Kianifard, Michelle Warren, James A. Simon. (2011) Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Menopause 18:8, 851-856
CrossRef86
Michael S. Ominsky, Brian Stouch, Joseph Schroeder, Ian Pyrah, Marina Stolina, Susan Y. Smith, Paul J. Kostenuik. (2011) Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 49:2, 162-173
CrossRef87
Ewa Sewerynek. (2011) Bisphosphonates and the risk of atrial fibrillation in elderly women with osteoporosis. Aging Health 7:4, 585-589
CrossRef88
Tahir Masud, Neil Binkley, Steven Boonen, Marian T. Hannan. (2011) Official Positions for FRAX® Clinical Regarding Falls and Frailty: Can Falls and Frailty be Used in FRAX®?. Journal of Clinical Densitometry 14:3, 194-204
CrossRef89
T-C Lin, C-Y Yang, Y-H Kao Yang, S-J Lin. (2011) Alendronate Adherence and Its Impact on Hip-Fracture Risk in Patients With Established Osteoporosis in Taiwan. Clinical Pharmacology & Therapeutics 90:1, 109-116
CrossRef90
Glen M. Blake, Michelle L. Frost, Amelia E.B. Moore, Musib Siddique, Ignac Fogelman. (2011) The Assessment of Regional Skeletal Metabolism: Studies of Osteoporosis Treatments Using Quantitative Radionuclide Imaging. Journal of Clinical Densitometry 14:3, 263-271
CrossRef91
Kelly R. Ragucci, Sarah P. Shrader. (2011) Osteoporosis Treatment: An Evidence-Based Approach. Journal of Gerontological Nursing 37:7, 17-22
CrossRef92
M. O. Premaor, T. K. Das, I. Debiram, R. A. Parker, M. Ninkovic, G. T. Alexander, J. E. Compston. (2011) Fracture incidence after liver transplantation: results of a 10-year audit. QJM 104:7, 599-606
CrossRef93
R. Graham G. Russell. (2011) Bisphosphonates: The first 40years. Bone 49:1, 2-19
CrossRef94
Richard Eastell, Jennifer S. Walsh, Nelson B. Watts, Ethel Siris. (2011) Bisphosphonates for postmenopausal osteoporosis. Bone 49:1, 82-88
CrossRef95
Michael Pazianas, Bo Abrahamsen. (2011) Safety of bisphosphonates. Bone 49:1, 103-110
CrossRef96
Frank H. Ebetino, Anne-Marie L. Hogan, Shuting Sun, Maria K. Tsoumpra, Xuchen Duan, James T. Triffitt, Aaron A. Kwaasi, James E. Dunford, Bobby L. Barnett, Udo Oppermann, Mark W. Lundy, Alan Boyde, Boris A. Kashemirov, Charles E. McKenna, R. Graham G. Russell. (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:1, 20-33
CrossRef97
Paul D. Miller. (2011) The kidney and bisphosphonates. Bone 49:1, 77-81
CrossRef98
Peggy M. Cawthon. (2011) Gender Differences in Osteoporosis and Fractures. Clinical Orthopaedics and Related Research® 469:7, 1900-1905
CrossRef99
I. R. Reid, M. J. Bolland, A. Avenell, A. Grey. (2011) Cardiovascular effects of calcium supplementation. Osteoporosis International 22:6, 1649-1658
CrossRef100
Ufuk Tatlı, Yakup Üstün, Mehmet Kürkçü, Özgür Erdoğan, Cihan Cem Gürbüz, Hülya Özgür, Sait Polat. (2011) Effects of Zoledronic Acid on Healing of Mandibular Fractures: An Experimental Study in Rabbits. Journal of Oral and Maxillofacial Surgery 69:6, 1726-1735
CrossRef101
R. Coleman, E. Woodward, J. Brown, D. Cameron, R. Bell, D. Dodwell, M. Keane, M. Gil, C. Davies, R. Burkinshaw, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee, H. Thorpe. (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment 127:2, 429-438
CrossRef102
P. Hadji. (2011) Managing bone health with zoledronic acid: a review of randomized clinical study results. Climacteric 14:3, 321-332
CrossRef103
Steven Boonen, Koen Milisen, Evelien Gielen, Dirk Vanderschueren. (2011) Sequential therapy in the treatment of osteoporosis. Current Medical Research and Opinion 27:6, 1149-1155
CrossRef104
Richard Eastell, Shinichi Nagase, Michiyo Ohyama, Maria Small, James Sawyer, Steven Boonen, Tim Spector, Tomohiro Kuwayama, Steve Deacon. (2011) Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. Journal of Bone and Mineral Research 26:6, 1303-1312
CrossRef105
Valerie Geoffroy, Eleftherios P. Paschalis, Helene Libouban, Stephane Blouin, Agnes Ostertag, Daniel Chappard, Magali Cros, Roger Phipps, Marie-Christine Vernejoul. (2011) Effects of Risedronate in Runx2 Overexpressing Mice, an Animal Model for Evaluation of Treatment Effects on Bone Quality and Fractures. Calcified Tissue International 88:6, 464-475
CrossRef106
S. Christensen, F. Mehnert, R. D. Chapurlat, J. A. Baron, H. T. Sørensen. (2011) Oral bisphosphonates and risk of ischemic stroke: a case–control study. Osteoporosis International 22:6, 1773-1779
CrossRef107
Manuel Sosa, Esther González-Padilla. (2011) Promising developments in osteoporosis treatment. International Journal of Clinical Rheumatology 6:3, 325-332
CrossRef108
Y. Yeh, D. Slovik, D. Carter, M. Clapp, W. Churchill, P. Reddy. (2011) Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline. Journal of Clinical Pharmacy and Therapeutics 36:3, 342-347
CrossRef109
Michele Zini. (2011) Osteoporosi. La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 7:2, 100-105
CrossRef110
Raid Aljumaily, Paul Mathew. (2011) Optimal Management of Bone Metastases in Prostate Cancer. Current Oncology Reports 13:3, 222-230
CrossRef111
Philip N. Sambrook, Stuart L. Silverman, Jane A. Cauley, Chris Recknor, Melvin Olson, Guoqin Su, Steven Boonen, Dennis Black, Jonathan D. Adachi. (2011) Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. Bone 48:6, 1298-1304
CrossRef112
Susan Ross, Ebony Samuels, Kerry Gairy, Sheikh Iqbal, Enkhe Badamgarav, Ethel Siris. (2011) A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence. Value in Health 14:4, 571-581
CrossRef113
Nesé Yuksel. (2011) Putting long-term adverse events of bisphosphonates into perspective. Canadian Pharmacists Journal 144:sp1, S13-S13.e1
CrossRef114
Michelle L Frost, Musib Siddique, Glen M Blake, Amelia EB Moore, Paul J Schleyer, Joel T Dunn, Edward J Somer, Paul K Marsden, Richard Eastell, Ignac Fogelman. (2011) Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography. Journal of Bone and Mineral Research 26:5, 1002-1011
CrossRef115
Jane A Cauley, Dennis Black, Steven Boonen, Steven R Cummings, Peter Mesenbrink, Lisa Palermo, Zulema Man, Peyman Hadji, Ian R Reid, . (2011) Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. Journal of Bone and Mineral Research 26:5, 984-992
CrossRef116
Bernard Cortet. (2011) Osteoporosis medications and renal failure. Joint Bone Spine 78:3, 228-229
CrossRef117
Christian M. Girgis, Markus J. Seibel. (2011) Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. Bone 48:5, 963-965
CrossRef118
Jawl-Shan Hwang, Lin-Show Chin, Jung-Fu Chen, Tzay-Shing Yang, Po-Quang Chen, Keh-Sung Tsai, Ping Chung Leung. (2011) The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism 29:3, 328-333
CrossRef119
Baojie Li, Jenny Fung Ling Chau, Xueying Wang, Wai Fook Leong. (2011) Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. Journal of Cellular Biochemistry 112:5, 1229-1242
CrossRef120
Polyzois Makras, Athanasios D. Anastasilakis, Stergios A. Polyzos, Ilias Bisbinas, Grigorios T. Sakellariou, Socrates E. Papapoulos. (2011) No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. Calcified Tissue International 88:5, 402-408
CrossRef121
Muneaki Ishijima, Hisashi Kurosawa, Haruka Kaneko, Kazuo Kaneko. 2011. Biomarkers in Osteoarthritis. , 39-54.
CrossRef122
Jochen Klaus, M M Haenle, C Schröter, G Adler, G von Boyen, M Reinshagen, C von Tirpitz. (2011) A Single Dose of Intravenous Zoledronate Prevents Glucocorticoid Therapy-Associated Bone Loss in Acute Flare of Crohn's Disease, a Randomized Controlled Trial. The American Journal of Gastroenterology 106:4, 786-793
CrossRef123
E. Michael Lewiecki. (2011) Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis. Drugs 71:6, 791-814
CrossRef124
Linda Brewer, David Williams, Alan Moore. (2011) Current and future treatment options in osteoporosis. European Journal of Clinical Pharmacology 67:4, 321-331
CrossRef125
Roland Baron, Serge Ferrari, R. Graham G. Russell. (2011) Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 48:4, 677-692
CrossRef126
Deborah T. Gold. (2011) Understanding Patient Compliance and Persistence with Osteoporosis Therapy. Drugs & Aging 28:4, 249-255
CrossRef127
R. Rizzoli. (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same?. QJM 104:4, 281-300
CrossRef128
Chris Recknor. (2011) Zoledronic acid for prevention and treatment of osteoporosis. Expert Opinion on Pharmacotherapy 12:5, 807-815
CrossRef129
Simon Spazzapan, Diana Crivellari, Philippe Bedard, Davide Lombardi, Gianmaria Miolo, Simona Scalone, Andrea Veronesi. (2011) Therapeutic management of breast cancer in the elderly. Expert Opinion on Pharmacotherapy 12:6, 945-960
CrossRef130
Tilman D Rachner, Sundeep Khosla, Lorenz C Hofbauer. (2011) Osteoporosis: now and the future. The Lancet 377:9773, 1276-1287
CrossRef131
D. L. Kendler, S. Palacios, D. A. Cox, J. Stock, J. Alam, S. A. Dowsett, J. Zanchetta. (2011) Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporosis International
CrossRef132
Stuart L. Silverman. (2011) Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy. Current Osteoporosis Reports 9:1, 4-5
CrossRef133
José Manuel Quesada Gómez, Josep Blanch Rubió, Manuel Díaz Curiel, Adolfo Díez Pérez. (2011) Calcium Citrate and Vitamin D in the Treatment of Osteoporosis. Clinical Drug Investigation1
CrossRef134
S. Lee, P. Glendenning, C. A. Inderjeeth. (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, 741-753
CrossRef135
Felicia Cosman, Erik Fink Eriksen, Chris Recknor, Paul D Miller, Núria Guañabens, Christian Kasperk, Philemon Papanastasiou, Aimee Readie, Hanumantha Rao, Jürg A Gasser, Christina Bucci-Rechtweg, Steven Boonen. (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. Journal of Bone and Mineral Research 26:3, 503-511
CrossRef136
George K. Istaphanous, Derek S. Wheeler, Steven J. Lisco, Aryeh Shander. (2011) Red blood cell transfusion in critically ill children: A narrative review*. Pediatric Critical Care Medicine 12:2, 174-183
CrossRef137
Sigrun Ressler, Brigitte Mlineritsch, Richard Greil. (2011) Zoledronic acid for adjuvant use in patients with breast cancer. Expert Review of Anticancer Therapy 11:3, 333-349
CrossRef138
Seung Sang Ko, V Craig Jordan. (2011) Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opinion on Pharmacotherapy 12:4, 657-674
CrossRef139
, L.-A. Fraser, G. Ioannidis, J. D. Adachi, L. Pickard, S. M. Kaiser, J. Prior, J. P. Brown, D. A. Hanley, W. P. Olszynski, T. Anastassiades, S. Jamal, R. Josse, D. Goltzman, A. Papaioannou. (2011) Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporosis International 22:3, 789-796
CrossRef140
Jennifer M Grossman. (2011) Osteoporosis prevention. Current Opinion in Rheumatology 23:2, 203-210
CrossRef141
Pooneh Salari Sharif, Mohammad Abdollahi, Bagher Larijani. (2011) Current, new and future treatments of osteoporosis. Rheumatology International 31:3, 289-300
CrossRef142
Cagatay Arslan, Sercan Aksoy, Omer Dizdar, Didem Dede, Hakan Harputluoglu, Kadri Altundag. (2011) Zoledronic acid and atrial fibrillation in cancer patients. Supportive Care in Cancer 19:3, 425-430
CrossRef143
GL Borromeo, CE Tsao, IB Darby, PR Ebeling. (2011) A review of the clinical implications of bisphosphonates in dentistry. Australian Dental Journal 56:1, 2-9
CrossRef144
Barbara C. Silva, John P. Bilezikian. (2011) New Approaches to the Treatment of Osteoporosis. Annual Review of Medicine 62:1, 307-322
CrossRef145
M. Pazianas. (2011) Osteonecrosis of the Jaw and the Role of Macrophages. JNCI Journal of the National Cancer Institute 103:3, 232-240
CrossRef146
S. W. Y. Tsang, C. H. Bow, E. Y. W. Chu, S. C. Yeung, C. C. Soong, A. W. C. Kung. (2011) Clinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with vertebral fracture. Osteoporosis International 22:2, 667-674
CrossRef147
Serge Cremers, Azeez Farooki. (2011) Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Annals of the New York Academy of Sciences 1218:1, 80-87
CrossRef148
Socrates E. Papapoulos. (2011) Use of bisphosphonates in the management of postmenopausal osteoporosis. Annals of the New York Academy of Sciences 1218:1, 15-32
CrossRef149
Kimberly McKenzie, J. Dennis Bobyn, Jacintha Roberts, Dorota Karabasz, Michael Tanzer. (2011) Bisphosphonate Remains Highly Localized After Elution From Porous Implants. Clinical Orthopaedics and Related Research® 469:2, 514-522
CrossRef150
Amy Edgington, Mary Ann Morgan. (2011) Looking Beyond Recurrence: Comorbidities in Cancer Survivors. Clinical Journal of Oncology Nursing 15:1, E3-E12
CrossRef151
S. J. Craig, P. P. Youssef, J. H. Vaile, L. Sullivan, J. F. Bleasel. (2011) Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic. Internal Medicine Journal 41:2, 186-190
CrossRef152
R. Rizzoli, K. Åkesson, M. Bouxsein, J. A. Kanis, N. Napoli, S. Papapoulos, J.-Y. Reginster, C. Cooper. (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis International 22:2, 373-390
CrossRef153
, S. Vasikaran, R. Eastell, O. Bruyère, A. J. Foldes, P. Garnero, A. Griesmacher, M. McClung, H. A. Morris, S. Silverman, T. Trenti, D. A. Wahl, C. Cooper, J. A. Kanis. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International 22:2, 391-420
CrossRef154
TJ Blokhuis, P Buma, N Verdonschot, M Gotthardt, T Hendriks. (2011) BMP-7 stimulates early diaphyseal fracture healing in estrogen deficient rats. Journal of Orthopaedic Researchn/a-n/a
CrossRef155
Mary Kamienski, Denise Tate, CPT Marielos Vega. (2011) The Silent Thief. Orthopaedic Nursing 30:3, 162-171
CrossRef156
Luis Pérez Edo. (2011) La inhibición del RANKL en el tratamiento de la osteoporosis: denosumab. Seminarios de la Fundación Española de Reumatología 12:1, 27-30
CrossRef157
Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Hwa Jung Kim, Keun-Suk Lee, Jung-Sil Ro, Yun-Hee Park, Jin-Suk Ahn, Young-Hyk Im, Seock-Ah Im, Moon-Hee Lee, Si-Young Kim. (2011) Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Research and Treatment 125:1, 99-106
CrossRef158
Robert B Hopkins, Ron Goeree, Eleanor Pullenayegum, Jonathan D Adachi, Alexandra Papaioannou, Feng Xie, Lehana Thabane. (2011) The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 12:1, 209
CrossRef159
Jang-Jaer Lee, Shih-Jung Cheng, Yi-Ping Wang, Jiiang-Huei Jeng, Chun-Pin Chiang, Sang-Heng Kok. (2011) Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases. Head & Neckn/a-n/a
CrossRef160
Aoife G. Cotter, Patrick W. G. Mallon. (2011) HIV infection and bone disease: implications for an aging population. Sexual Health 8:4, 493
CrossRef161
Johan Halse. (2011) Blåreseptordningen disfavoriserer osteoporosepasienter. Tidsskrift for Den norske legeforening 131:9-10, 933-933
CrossRef162
Li Gong, Russ B. Altman, Teri E. Klein. (2011) Bisphosphonates pathway. Pharmacogenetics and Genomics 21:1, 50-53
CrossRef163
Jean-Yves Reginster. (2011) Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis. Drugs 71:1, 65-78
CrossRef164
Eleftheria Panteliou, Neil Young, Morag Naysmith. (2011) Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report. Journal of Medical Case Reports 5:1, 367
CrossRef165
B. Cvikl, H. Agis, K. Stögerer, A. Moritz, G. Watzek, R. Gruber. (2011) The response of dental pulp-derived cells to zoledronate depends on the experimental model. International Endodontic Journal 44:1, 33-40
CrossRef166
Helen Karga, Irene Giagourta, Garyphallia Papaioannou, Paraskevi Katsichti, Argyris Pardalakis, Georgia Kassi, Apostolia Zagoreou, Maria Triantaphyllopoulou, Cherry Zerva. (2011) Transient changes in thyroid functions tests after zoledronic acid infusion. Endocrine Journal 58:11, 969-977
CrossRef167
Kyung-Wook Kim, Beom-Jin Kim, Chung-Hyun Lee. (2011) Clinical study of diagnosis and treatment of bisphosphonate-related osteonecrosis of the jaws. Journal of the Korean Association of Oral and Maxillofacial Surgeons 37:1, 54
CrossRef168
Unni Syversen, Johan Halse. (2011) Bisfosfonatbehandling av osteoporose og andre skjelettsykdommer. Tidsskrift for Den norske legeforening 131:3, 244-247
CrossRef169
Xinmin Zhao, Xiaofeng Xu, Qunling Zhang, Zhen Jia, Si Sun, Jian Zhang, Biyun Wang, Zhonghua Wang, Xichun Hu. (2011) Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. BMC Cancer 11:1, 403
CrossRef170
Gelsomina L Borromeo, Caroline Brand, John G Clement, Michael McCullough, Wendy Thomson, Elly Flitzanis, John D Wark. (2011) Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskeletal Disorders 12:1, 71
CrossRef171
Luis Arboleya, Mercedes Alperi, Sara Alonso. (2011) Adverse effects of bisphosphonates. Reumatolog ía Cl ínica (English Edition) 7:3, 189-197
CrossRef172
Stergios A. Polyzos. (2011) Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget’s disease of bone. Clinical Rheumatology 30:1, 149-150
CrossRef173
J. S. Bubbear, A. Gall, F. R. I. Middleton, M. Ferguson-Pell, R. Swaminathan, R. W. Keen. (2011) Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporosis International 22:1, 271-279
CrossRef174
Unni Syversen, Johan Halse, Jürgen Geisler, Erik Eriksen. (2011) Denosumab for behandling av postmenopausal osteoporose. Tidsskrift for Den norske legeforening 131:19, 1893-1896
CrossRef175
Sonja Gamsjaeger, Birgit Buchinger, Elizabeth Zwettler, Robert Recker, Dennis Black, Juerg A Gasser, Erik F Eriksen, Klaus Klaushofer, Eleftherios P Paschalis. (2011) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. Journal of Bone and Mineral Research 26:1, 12-18
CrossRef176
E. Michael Lewiecki, John P. Bilezikian, Sundeep Khosla, Robert Marcus, Michael R. McClung, Paul D. Miller, Nelson B. Watts, Michael Maricic. (2011) Osteoporosis Update From the 2010 Santa Fe Bone Symposium. Journal of Clinical Densitometry 14:1, 1-21
CrossRef177
Sven Otto, Karl Sotlar, Michael Ehrenfeld, Christoph Pautke. (2011) Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report. Journal of Medical Case Reports 5:1, 477
CrossRef178
D.M. Black, I.R. Reid, S. Boonen, C. Bucci-Rechtweg, J.A. Cauley, F. Cosman, S.R. Cummings, T.F. Hue, K. Lippuner, P. Lakatos, P.C. Leung, Z. Man, R. Martinez, M. Tan, M.E. Ruzycky, G. Su, R. Eastell. (2011) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Researchn/a-n/a
CrossRef179
K. Briot. (2011) Osteoporosis posmenopáusica. EMC - Aparato Locomotor 44:4, 1-11
CrossRef180
Peter R. Ebeling, John A. Eisman. 2011. Vitamin D and Osteoporosis. , 1129-1144.
CrossRef181
Romina Ruscica, Micaela Bianchi, Mariano Quintero, Andrea Martinez, Daniel R. Vega. (2010) Solid-state forms of zoledronic acid: Polymorphism in hydrates. Journal of Pharmaceutical Sciences 99:12, 4962-4972
CrossRef182
Julien Paccou, Cyrille B. Confavreux, Claire David, Ariane Leboime, Nadia Mehsen, Bernard Cortet. (2010) Stabilized severe osteoporosis: should the treatment be stopped?. Joint Bone Spine 77, S120-S127
CrossRef183
S. J. Gallacher, T. Dixon. (2010) Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review. Calcified Tissue International 87:6, 469-484
CrossRef184
Y. A. Hundrup, R. K. Jacobsen, A. H. Andreasen, M. Davidsen, E. B. Obel, B. Abrahamsen. (2010) Validation of a 5-year risk score of hip fracture in postmenopausal women. The Danish Nurse Cohort Study. Osteoporosis International 21:12, 2135-2142
CrossRef185
E. Michael Lewiecki. (2010) Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Current Medical Research and Opinion 26:12, 2807-2812
CrossRef186
Patricia A. Howard, Brian J. Barnes, James L. Vacek, Warren Chen, Sue-Min Lai. (2010) Impact of Bisphosphonates on the Risk of Atrial Fibrillation. American Journal Cardiovascular Drugs 10:6, 359-367
CrossRef187
T. P. Ip, J. Leung, A. W. C. Kung. (2010) Management of osteoporosis in patients hospitalized for hip fractures. Osteoporosis International 21:S4, 605-614
CrossRef188
Hyosook Hwang, Sharon L Hale, Justin Leeka, Robert A Kloner. (2010) Effects of Zoledronate in the Repair of Chronically Infarcted Rat Myocardium. Journal of Cardiovascular Pharmacology 56:6, 604-609
CrossRef189
Ticiana Leal, Amyé Tevaarwerk, Richard Love, James Stewart, Neil Binkley, Jens Eickhoff, Benjamin Parrot, Daniel Mulkerin. (2010) Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer. Clinical Breast Cancer 10:6, 471-476
CrossRef190
E. Michael Lewiecki. (2010) Monitoring pharmacological therapy for osteoporosis. Reviews in Endocrine and Metabolic Disorders 11:4, 261-273
CrossRef191
Xinmin Zhao, Xiaofeng Xu, Lin Guo, Joseph Ragaz, Haiyi Guo, Jiong Wu, Zhimin Shao, Ji Zhu, Xiaomao Guo, Jiayi Chen, Beiling Zhu, Zhonghua Wang, Xichun Hu. (2010) Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Research and Treatment 124:3, 733-743
CrossRef192
M. J. Bolland, A. Grey, G. D. Gamble, I. R. Reid. (2010) Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice 64:13, 1719-1722
CrossRef193
Cyrille B. Confavreux, Julien Paccou, Claire David, Nadia Mehsen, Ariane Leboime, Thierry Thomas. (2010) Defining treatment failure in severe osteoporosis. Joint Bone Spine 77, S128-S132
CrossRef194
Favus, Murray J., . (2010) Bisphosphonates for Osteoporosis. New England Journal of Medicine 363:21, 2027-2035
Full Text195
, E. Noon, S. Singh, J. Cuzick, T. D. Spector, F. M. K. Williams, M. L. Frost, A. Howell, M. Harvie, R. Eastell, R. E. Coleman, I. Fogelman, G. M. Blake. (2010) Significant differences in UK and US female bone density reference ranges. Osteoporosis International 21:11, 1871-1880
CrossRef196
Douglas A. Johnson, Melissa I. Williams, Valentina I. Petkov, Robert A. Adler. (2010) Zoledronic Acid Treatment of Osteoporosis: Effects in Men. Endocrine Practice 16:6, 960-967
CrossRef197
Sammy Elmariah, Joseph A.C. Delaney, Kevin D. O'Brien, Matthew J. Budoff, Jens Vogel-Claussen, Valentin Fuster, Richard A. Kronmal, Jonathan L. Halperin. (2010) Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women. Journal of the American College of Cardiology 56:21, 1752-1759
CrossRef198
Henning T Mouridsen, Per Lønning, Matthias W Beckmann, Kimberly Blackwell, Julie Doughty, Joseph Gligorov, Antonio Llombart-Cussac, Andre Robidoux, Beat Thürlimann, Michael Gnant. (2010) Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy 10:11, 1825-1836
CrossRef199
Stuart L. Silverman. (2010) Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies. Calcified Tissue International 87:5, 375-384
CrossRef200
A. L. Lamberg, E. Horvath-Puho, S. Christensen, H. T. Sørensen. (2010) Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study. Osteoporosis International 21:11, 1911-1917
CrossRef201
(2010) Bone fractures after menopause. Human Reproduction Update 16:6, 761-773
CrossRef202
M. H. Vieillard, J. Paccou, B. Cortet, E. Biver, J. Salleron, G. Falgayrac, G. Penel. (2010) Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporosis International 21:11, 1919-1925
CrossRef203
P. D. Miller, R. J. Derman. (2010) What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteoporosis International 21:11, 1793-1802
CrossRef204
Audrey Juillard, Guillaume Falgayrac, Bernard Cortet, Marie-Hélène Vieillard, Nathalie Azaroual, Jean-Christophe Hornez, Guillaume Penel. (2010) Molecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study. Bone 47:5, 895-904
CrossRef205
J. S. B. Carvas, R. M. R. Pereira, V. F. Caparbo, P. Fuller, C. A. Silveira, L. A. P. Lima, E. Bonfa, S. B. V. Mello. (2010) A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration. Osteoporosis International 21:10, 1723-1729
CrossRef206
David A. Cameron, Sharon Douglas, Janet E. Brown, Richard A. Anderson. (2010) Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. Breast Cancer Research and Treatment 123:3, 805-814
CrossRef207
Ian R Reid, Paul D Miller, Jacques P Brown, David L Kendler, Astrid Fahrleitner-Pammer, Ivo Valter, Katre Maasalu, Michael A Bolognese, Grattan Woodson, Henry Bone, Beiying Ding, Rachel B Wagman, Javier San Martin, Michael S Ominsky, David W Dempster. (2010) Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. Journal of Bone and Mineral Research 25:10, 2256-2265
CrossRef208
Anne Marie Sbrocchi, Sylviane Forget, Diane Laforte, E. Michel Azouz, Celia Rodd. (2010) Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatrics International 52:5, 754-761
CrossRef209
Michael Maricic. (2010) The role of zoledronic acid in the management of osteoporosis. Clinical Rheumatology 29:10, 1079-1084
CrossRef210
J.-J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster. (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International 21:10, 1657-1680
CrossRef211
Ronald C. Hamdy, Sanford Baim, Susan B. Broy, E. Michael Lewiecki, Sarah L. Morgan, S. Bobo Tanner, Howard F. Williamson. (2010) Algorithm for the Management of Osteoporosis. Southern Medical Journal 103:10, 1009-1017
CrossRef212
Andrew Grey, Mark Bolland, Diana Wattie, Anne Horne, Greg Gamble, Ian R Reid. (2010) Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. Journal of Bone and Mineral Research 25:10, 2251-2255
CrossRef213
Eric S Orwoll, Paul D Miller, Jonathan D Adachi, Jacques Brown, Robert A Adler, David Kendler, Christina Bucci-Rechtweg, Aimee Readie, Peter Mesenbrink, Robert S Weinstein. (2010) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study. Journal of Bone and Mineral Research 25:10, 2239-2250
CrossRef214
Stein, C. Michael, Ray, Wayne A., . (2010) The Ethics of Placebo in Studies with Fracture End Points in Osteoporosis. New England Journal of Medicine 363:14, 1367-1370
Full Text215
Ernesto Canalis. (2010) New Treatment Modalities in Osteoporosis. Endocrine Practice 16:5, 855-863
CrossRef216
E. Michael Lewiecki. (2010) Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond. Clinical Reviews in Bone and Mineral Metabolism 8:3, 101-112
CrossRef217
George P. Lyritis, Thomas Georgoulas, Christos P Zafeiris. (2010) Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Annals of the New York Academy of Sciences 1205:1, 277-283
CrossRef218
Abhishek Banerjee, Bassem S. Bassil, Gerd-Volker Röschenthaler, Ulrich Kortz. (2010) Fluorine Tagging of Polyoxometalates: The Cyclic [{MoV2O4(H2O)}4{O3PC(CF3)(O)PO3}4]12-. European Journal of Inorganic Chemistry 2010:25, 3915-3919
CrossRef219
H. Taggart, J. Cheng, P. Archbold. (2010) Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis. Osteoporosis International 21:9, 1621-1622
CrossRef220
Marcy B. Bolster. (2010) Osteoporosis and Bone Health in Patients with Lung Disease. Clinics in Chest Medicine 31:3, 555-563
CrossRef221
G. R. Werner de Castro, F. S. Neves, S. C. Magalhães Souza Fialho, I. A. Pereira, G. Ribeiro, A. F. Zimmermann. (2010) Flare-up of hand osteoarthritis caused by zoledronic acid infusion. Osteoporosis International 21:9, 1617-1619
CrossRef222
Peter Pietschmann, Ursula Azizi-Semrad, Katharina Pils, Astrid Fahrleitner-Pammer, Heinrich Resch, Harald Dobnig. (2010) Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences. Wiener klinische Wochenschrift 122:17-18, 532-537
CrossRef223
John J. Carey, Miriam F. Delaney. (2010) T-Scores and Z-Scores. Clinical Reviews in Bone and Mineral Metabolism 8:3, 113-121
CrossRef224
Peter Vestergaard. (2010) Risk factors for second hip fractures. International Journal of Clinical Rheumatology 5:4, 415-417
CrossRef225
Thomas E. Delea, Charu Taneja, Oleg Sofrygin, Satyin Kaura, Michael Gnant. (2010) Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormone-Responsive Early Breast Cancer. Clinical Breast Cancer 10:4, 267-274
CrossRef226
Michael Davie, Paula Jeffreson, Teresa Jones, Tracey Roberts, Femi Adekunle, Paul Mitchell. (2010) Peripatetic intravenous service for metabolic bone disease: case study in patient centred-care for new NHS. Current Medical Research and Opinion 26:8, 2033-2039
CrossRef227
Helmut Radspieler. (2010) Individualized treatment of osteoporosis with medication: preventing fractures by increasing bone mineralization and quality. International Journal of Clinical Rheumatology 5:4, 451-459
CrossRef228
Hesham A. Habib, Beatriz Gil-Hernández, Khalid Abu-Shandi, Joaquín Sanchiz, Christoph Janiak. (2010) Iron, copper and zinc ammonium-1-hydroxyalkylidene-diphosphonates with zero-, one- and two-dimensional covalent metal–ligand structures extended into three-dimensional supramolecular networks by charge-assisted hydrogen-bonding. Polyhedron 29:12, 2537-2545
CrossRef229
Tamara D. Rozental, Jalaal Shah, Aron T. Chacko, David Zurakowski. (2010) Prevalence and Predictors of Osteoporosis Risk in Orthopaedic Patients. Clinical Orthopaedics and Related Research® 468:7, 1765-1772
CrossRef230
J. Øyen, C. G. Gjesdal, C. Brudvik, L. M. Hove, E. M. Apalset, H. C. Gulseth, G. Haugeberg. (2010) Low-energy distal radius fractures in middle-aged and elderly men and women—the burden of osteoporosis and fracture risk. Osteoporosis International 21:7, 1257-1267
CrossRef231
Bo Abrahamsen. (2010) Bisphosphonate adverse effects, lessons from large databases. Current Opinion in Rheumatology 22:4, 404-409
CrossRef232
, R. Eastell, T. Lang, S. Boonen, S. Cummings, P. D. Delmas, J. A. Cauley, Z. Horowitz, E. Kerzberg, G. Bianchi, D. Kendler, P. Leung, Z. Man, P. Mesenbrink, E. F. Eriksen, D. M. Black. (2010) Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis International 21:7, 1277-1285
CrossRef233
KS Brar. (2010) Prevalent and emerging therapies for osteoporosis. Medical Journal Armed Forces India 66:3, 249-254
CrossRef234
Rohit Bhuriya, Mukesh Singh, Janos Molnar, Rohit Arora, Sandeep Khosla. (2010) Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis. International Journal of Cardiology 142:3, 213-217
CrossRef235
Reinhard Gruber. (2010) Osteoporose – Risikofaktor in der Zahnheilkunde?. Stomatologie 107:4, 55-60
CrossRef236
José A. Riancho. (2010) Genetics of Osteoporosis: Half-Full or Half-Empty?. Clinical Reviews in Bone and Mineral Metabolism 8:2, 49-50
CrossRef237
Bo Abrahamsen. (2010) Adverse Effects of Bisphosphonates. Calcified Tissue International 86:6, 421-435
CrossRef238
Black, Dennis M., Kelly, Michael P., Genant, Harry K., Palermo, Lisa, Eastell, Richard, Bucci-Rechtweg, Christina, Cauley, Jane, Leung, Ping Chung, Boonen, Steven, Santora, Arthur, de Papp, Anne, Bauer, Douglas C., . (2010) Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. New England Journal of Medicine 362:19, 1761-1771
Full Text239
Peter Vestergaard, Kristoffer Schwartz, Else Marie Pinholt, Lars Rejnmark, Leif Mosekilde. (2010) Risk of Atrial Fibrillation Associated with Use of Bisphosphonates and Other Drugs Against Osteoporosis: A Cohort Study. Calcified Tissue International 86:5, 335-342
CrossRef240
E. M. Lewiecki, C. Cooper, E. Thompson, F. Hartl, D. Mehta, S. E. Papapoulos. (2010) Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. International Journal of Clinical Practice 64:6, 821-826
CrossRef241
Daniele Diacinti, Giuseppe Guglielmi. (2010) Vertebral Morphometry. Radiologic Clinics of North America 48:3, 561-575
CrossRef242
Johann D. Ringe, John G. Doherty. (2010) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatology International 30:7, 863-869
CrossRef243
Mohammad Shahnazari, Wei Yao, WeiWei Dai, Bob Wang, Sophi S. Ionova-Martin, Robert O. Ritchie, Daniel Heeren, Andrew J. Burghardt, Daniel P. Nicolella, Michael G. Kimiecik, Nancy E. Lane. (2010) Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 46:5, 1267-1274
CrossRef244
María Jesús Moro-Álvarez, Manuel Díaz-Curiel. (2010) Diagnóstico y tratamiento de la osteoporosis en mayores de 75 años. Revista Española de Geriatría y Gerontología 45:3, 141-149
CrossRef245
Ina Kramer, Hansjoerg Keller, Olivier Leupin, Michaela Kneissel. (2010) Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends in Endocrinology & Metabolism 21:4, 237-244
CrossRef246
Jan L. Shifren, Isaac Schiff. (2010) Role of Hormone Therapy in the Management of Menopause. Obstetrics & Gynecology 115:4, 839-855
CrossRef247
M. M. Wilkes, R. J. Navickis, W. W. Chan, E. M. Lewiecki. (2010) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporosis International 21:4, 679-688
CrossRef248
James A. Simon. (2010) Are All Bisphosphonates the Same? Potential Reasons for Clinical Differences: A Perspective. Journal of Women's Health 19:4, 719-727
CrossRef249
Eric S. Orwoll, Neil C. Binkley, E. Michael Lewiecki, Ugis Gruntmanis, Michael A. Fries, Gorana Dasic. (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:4, 970-976
CrossRef250
K.-S. Delank, M. Röllinghoff, K. Eysel-Gosepath, R. Sobottke, P. Eysel. (2010) Degeneration und Osteoporose der Wirbelsäule. Der Orthopäde 39:4, 425-431
CrossRef251
Paul D. Miller. (2010) All Bisphosphonates Are (or May Not Be) the Same: Potential Reasons for Clinical Differences. Journal of Women's Health 19:4, 665-669
CrossRef252
Ego Seeman, Steven Boonen, Frederik Borgström, Bruno Vellas, Jean-Pierre Aquino, Jutta Semler, Claude-Laurent Benhamou, Jean-Marc Kaufman, Jean-Yves Reginster. (2010) Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 46:4, 1038-1042
CrossRef253
Michael Kühne, David Conen. (2010) Atrial fibrillation in women. Therapy 7:2, 139-146
CrossRef254
E. Biver, M.H. Vieillard, B. Cortet, J. Salleron, G. Falgayrac, G. Penel. (2010) No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site. Bone 46:3, 643-648
CrossRef255
B. Abrahamsen, P. Vestergaard. (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006. Osteoporosis International 21:3, 373-380
CrossRef256
Francesco Bertoldo, Serena Pancheri, Sonia Zenari, Stefania Boldini, Benedetta Giovanazzi, Mirko Zanatta, Maria Teresa Valenti, Luca Dalle Carbonare, Vincenzo Lo Cascio. (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. Journal of Bone and Mineral Research 25:3, 447-454
CrossRef257
Michael Maricic. (2010) Intravenous Zoledronic Acid: What Are the Indications for Male Osteoporosis?. Current Osteoporosis Reports 8:1, 4-9
CrossRef258
Janaka Lenora, Kaisa K. Ivaska, Paul Gerdhem. (2010) Use of Bone Turnover Markers in Osteoporosis. Clinical Reviews in Bone and Mineral Metabolism 8:1, 1-14
CrossRef259
A. John Camm. (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clinical Therapeutics 32:3, 426-436
CrossRef260
Robert A. Adler. (2010) Glucocorticoid-Induced Osteoporosis: Management Update. Current Osteoporosis Reports 8:1, 10-14
CrossRef261
Mickaël Hiligsmann, Véronique Rabenda, Henry-Jean Gathon, Olivier Ethgen, Jean-Yves Reginster. (2010) Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcified Tissue International 86:3, 202-210
CrossRef262
Edward T Middleton, Susan A Steel, Mo Aye, Sheelagh M Doherty. (2010) The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. Journal of Bone and Mineral Research 25:3, 455-462
CrossRef263
Alper Yıldız, Emin Esen, Mehmet Kürkçü, İbrahim Damlar, Kenan Dağlıoğlu, Tolga Akova. (2010) Effect of Zoledronic Acid on Osseointegration of Titanium Implants: An Experimental Study in an Ovariectomized Rabbit Model. Journal of Oral and Maxillofacial Surgery 68:3, 515-523
CrossRef264
Pongthorn Narongroeknawin, Maria I. Danila, Lewis G. Humphreys Jr, Andrei Barasch, Jeffrey R. Curtis. (2010) Bisphosphonate-associated osteonecrosis of the jaw,with healing after teriparatide:a review of the literature and a case report. Special Care in Dentistry 30:2, 77-82
CrossRef265
K. Lippuner, H. Johansson, J. A. Kanis, R. Rizzoli. (2010) FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporosis International 21:3, 381-389
CrossRef266
Cummings, Steven R., Ensrud, Kristine, Delmas, Pierre D., LaCroix, Andrea Z., Vukicevic, Slobodan, Reid, David M., Goldstein, Steven, Sriram, Usha, Lee, Andy, Thompson, John, Armstrong, Roisin A., Thompson, David D., Powles, Trevor, Zanchetta, Jose, Kendler, David, Neven, Patrick, Eastell, Richard, . (2010) Lasofoxifene in Postmenopausal Women with Osteoporosis. New England Journal of Medicine 362:8, 686-696
Full Text267
Teun M. Post, Serge C.L.M. Cremers, Thomas Kerbusch, Meindert Danhof. (2010) Bone Physiology, Disease and Treatment. Clinical Pharmacokinetics 49:2, 89-118
CrossRef268
Peter C. Austin, Andrea Manca, Merrick Zwarenstein, David N. Juurlink, Matthew B. Stanbrook. (2010) A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology 63:2, 142-153
CrossRef269
Patrick G. Morris, Catherine Van Poznak, Shanu Modi, Alex F. Mak, Sujata Patil, Steven Larson, Clifford A. Hudis, Chaitanya Divgi, Ravinder K. Grewal. (2010) Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results. Clinical Breast Cancer 10:1, 33-39
CrossRef270
Ben-Hur Albergaria, Brenda Nazaré Gomes Silva, Álvaro N Atallah, Virginia Fernandes Moça Trevisani, Ben-Hur Albergaria. 2010. Intravenous zoledronate for postmenopausal osteoporosis. .
CrossRef271
Eitan Amir, Christine E. Simmons, Orit C. Freedman, George Dranitsaris, David E. C. Cole, Reinhold Vieth, Wei S. Ooi, Mark Clemons. (2010) A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D 3 in breast cancer patients with bone metastases. Cancer 116:2, 284-291
CrossRef272
Marc C. Hochberg. 2010. Osteoporosis. , 317-329.
CrossRef273
Matthew R Allen, Daniel J Kubek, David B Burr. (2010) Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. Journal of Bone and Mineral Research 25:1, 98-105
CrossRef274
Cathleen S Colón-Emeric, Peter Mesenbrink, Kenneth W Lyles, Carl F Pieper, Steven Boonen, Pierre Delmas, Erik F Eriksen, Jay Magaziner. (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. Journal of Bone and Mineral Research 25:1, 91-97
CrossRef275
Glen M. Blake, Ignac Fogelman. (2010) An Update on Dual-Energy X-Ray Absorptiometry. Seminars in Nuclear Medicine 40:1, 62-73
CrossRef276
J. Chris Gallagher, Adarsh J. Sai. (2010) Bisphosphonate use in osteoporosis. Menopause 17:1, 5-7
CrossRef277
Anne L Langston, Marion K Campbell, William D Fraser, Graeme S MacLennan, Peter L Selby, Stuart H Ralston. (2010) Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone. Journal of Bone and Mineral Research 25:1, 20-31
CrossRef278
M. Mamtani, H. Kulkarni. (2010) Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporosis International 21:1, 183-187
CrossRef279
José Luis Pérez-Castrillón, Florentino Pinacho, Daniel De Luis, María Lopez-Menendez, Antonio Dueñas Laita. (2010) Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women. Journal of Osteoporosis 2010, 1-5
CrossRef280
M. A. Lawson, Z. Xia, B. L. Barnett, J. T. Triffitt, R. J. Phipps, J. E. Dunford, R. M. Locklin, F. H. Ebetino, R. G. G. Russell. (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. Journal of Biomedical Materials Research Part B: Applied Biomaterials 92B:1, 149-155
CrossRef281
Robert John W. Knight, Chaithan Reddy, Michael A. Rtshiladze, Gregory Lvoff, David Sherring, Damian Marucci. (2010) Bisphosphonate-Related Osteonecrosis of the Jaw. Journal of Craniofacial Surgery 21:1, 25-32
CrossRef282
&NA;. (2010) Management of osteoporosis in postmenopausal women. Menopause 17:1, 25-54
CrossRef283
Melissa Thompson, Margaret Pasquale, Daniel Grima, Werner Moehrke, Hans Peter Kruse. (2010) The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis. Value in Health 13:1, 46-54
CrossRef284
Weng-Foung Huang, Yi-Wen Tsai, Yu-Wen Wen, Fei-Yuan Hsiao, Ken N. Kuo, Chia-Rung Tsai. (2010) Osteoporosis treatment and atrial fibrillation. Menopause 17:1, 57-63
CrossRef285
Michael Pazianas, Juliet Compston, Christopher L-H Huang. (2010) Atrial fibrillation and bisphosphonate therapy. Journal of Bone and Mineral Research 25:1, 2-10
CrossRef286
Patrice Fardellone, Bernard Cortet, Erick Legrand, Xavier Bresse, Ségolène Bisot-Locard, Anne-Marie Vigneron, Ariel Beresniak. (2010) Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis. Joint Bone Spine 77:1, 53-57
CrossRef287
Kendall F. Moseley, Suzanne M. Jan de Beur. 2010. Osteoporosis in Men and Women. , 716-736.
CrossRef288
P MILLER. 2010. Management of Fractures in Men with Impaired Renal Function. , 453-463.
CrossRef289
Juliet Compston. (2009) Monitoring osteoporosis treatment. Best Practice & Research Clinical Rheumatology 23:6, 781-788
CrossRef290
Salvatore L. Ruggiero, Thomas B. Dodson, Leon A. Assael, Regina Landesberg, Robert E. Marx, Bhoomi Mehrotra. (2009) American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw â 2009 Update. Australian Endodontic Journal 35:3, 119-130
CrossRef291
K. Kayan, H. Johansson, A. Oden, S. Vasireddy, K. Pande, J. Orgee, J. A. Kanis, E. V. McCloskey. (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporosis International 20:12, 2055-2061
CrossRef292
R. Bartl, C. Bartl, R. Gradinger. (2009) Medikamenteninduzierte Osteopathien. Der Orthopäde 38:12, 1245-1261
CrossRef293
Yong-Dae Kwon, Deog-Yoon Kim, Joo-Young Ohe, Ji-Yeon Yoo, Christian Walter. (2009) Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery 67:12, 2644-2648
CrossRef294
S. Boonen, R. Kay, C. Cooper, P. Haentjens, D. Vanderschueren, F. Callewaert, K. Milisen, S. Ferrari. (2009) Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. International Journal of Clinical Practice 63:12, 1792-1804
CrossRef295
Peter R. Ebeling. (2009) Metabolic bone diseases: Translational research—preventing fractures with denosumab. Nature Reviews Rheumatology 5:12, 660-661
CrossRef296
S. Epstein, M. Jeglitsch, E. McCloskey. (2009) Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Current Medical Research and Opinion 25:12, 2951-2960
CrossRef297
Andrew Rosenzweig, Richa Mishra. (2009) Evaluation and management of osteoporosis and fragility fractures in the elderly. Aging Health 5:6, 833-850
CrossRef298
Johann D. Ringe, Gerd Möller. (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatology International 30:2, 213-221
CrossRef299
Dane K. Wukich, Wenjay Sung. (2009) Charcot arthropathy of the foot and ankle: modern concepts and management review. Journal of Diabetes and its Complications 23:6, 409-426
CrossRef300
Glen M. Blake, Amelia E.B. Moore, Ignac Fogelman. (2009) Quantitative Studies of Bone Using 99mTc-Methylene Diphosphonate Skeletal Plasma Clearance. Seminars in Nuclear Medicine 39:6, 369-379
CrossRef301
Naomi Kemeny-Suss, Amanda Kasneci, Daniel Rivas, Jonathan Afilalo, Svetlana V. Komarova, Lorraine E. Chalifour, Gustavo Duque. (2009) Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascular Pharmacology 51:5-6, 350-358
CrossRef302
Michael McClung, Paul Miller, Chris Recknor, Peter Mesenbrink, Christina Bucci-Rechtweg, Claude-Laurent Benhamou. (2009) Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology 114:5, 999-1007
CrossRef303
Nirmala Bhoopalam, Steven C. Campbell, Thomas Moritz, William R. Broderick, Padmini Iyer, Anthony G. Arcenas, Peter J. Van Veldhuizen, Nicholas Friedman, Domenic Reda, Stuart Warren, Harinder Garewal. (2009) Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy. The Journal of Urology 182:5, 2257-2264
CrossRef304
Steven Boonen. (2009) Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective. Current Medical Research and Opinion 25:10, 2335-2341
CrossRef305
Stephanie L. Hines, Betty Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Miroslaw A. Mazurczak, Daniel A. Nikcevich, Charles L. Loprinzi. (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Research and Treatment 117:3, 603-609
CrossRef306
R. Rizzoli, O. Bruyere, J. B. Cannata-Andia, J.-P. Devogelaer, G. Lyritis, J. D. Ringe, B. Vellas, J.-Y. Reginster. (2009) Management of osteoporosis in the elderly. Current Medical Research and Opinion 25:10, 2373-2387
CrossRef307
S. Greiner, A. Kadow-Romacker, G. Schmidmaier, B. Wildemann. (2009) Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. Journal of Biomedical Materials Research Part A 91A:1, 288-295
CrossRef308
S. Ferrari. (2009) Continuous broad protection against osteoporotic fractures with strontium ranelate. Rheumatology 48:Supplement 4, iv20-iv24
CrossRef309
Sheila A Doggrell. (2009) Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget’s bone disease. Expert Review of Endocrinology & Metabolism 4:5, 405-415
CrossRef310
Glen M. Blake, Ignac Fogelman. (2009) The clinical role of dual energy X-ray absorptiometry. European Journal of Radiology 71:3, 406-414
CrossRef311
Stuart L. Silverman. (2009) New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab. Current Osteoporosis Reports 7:3, 91-95
CrossRef312
Jun Iwamoto, Yoshihiro Sato, Tsuyoshi Takeda, Hideo Matsumoto. (2009) Role of sport and exercise in the maintenance of female bone health. Journal of Bone and Mineral Metabolism 27:5, 530-537
CrossRef313
Juliet Compston. (2009) Clinical and therapeutic aspects of osteoporosis. European Journal of Radiology 71:3, 388-391
CrossRef314
Sheila A Doggrell. (2009) Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Review of Anticancer Therapy 9:9, 1211-1218
CrossRef315
E. Michael Lewiecki, Neil Binkley. (2009) Evidence-Based Medicine, Clinical Practice Guidelines, and Common Sense in the Management of Osteoporosis. Endocrine Practice 15:6, 573-579
CrossRef316
J. R. Curtis, A. Laster, D. J. Becker, L. Carbone, L. C. Gary, M. L. Kilgore, R. S. Matthews, M. A. Morrisey, K. G. Saag, S. B. Tanner, E. Delzell. (2009) The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporosis International 20:9, 1553-1561
CrossRef317
Abby N. Agulnek, Kevin J. O'Leary, Beatrice J. Edwards. (2009) Acute vertebral fracture. Journal of Hospital Medicine 4:7, E20-E24
CrossRef318
G. Weryha, B. Weryha, M. Rancier, M. Klein, A. Benetos. (2009) L’ostéoporose chez l’homme âgé. Les cahiers de l'année gérontologique 1:3, 188-194
CrossRef319
Stergios A Polyzos, Athanasios D Anastasilakis, Evangelos Terpos. (2009) Paget’s disease of bone: emphasis on treatment with zoledronic acid. Expert Review of Endocrinology & Metabolism 4:5, 423-434
CrossRef320
Bart L. Clarke. (2009) New and emerging treatments for osteoporosis. Clinical Endocrinology 71:3, 309-321
CrossRef321
Beth Nochowitz, Sherry Siegert, Mitzi Wasik. (2009) An Update on Osteoporosis. American Journal of Therapeutics 16:5, 437-445
CrossRef322
D. J. Leeming, K. Henriksen, I. Byrjalsen, P. Qvist, S. H. Madsen, P. Garnero, M. A. Karsdal. (2009) Is bone quality associated with collagen age?. Osteoporosis International 20:9, 1461-1470
CrossRef323
Murali Sundaram. (2009) Founders lecture 2007. Skeletal Radiology 38:9, 841-853
CrossRef324
Cummings, Steven R., Martin, Javier San, McClung, Michael R., Siris, Ethel S., Eastell, Richard, Reid, Ian R., Delmas, Pierre, Zoog, Holly B., Austin, Matt, Wang, Andrea, Kutilek, Stepan, Adami, Silvano, Zanchetta, Jose, Libanati, Cesar, Siddhanti, Suresh, Christiansen, Claus, . (2009) Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine 361:8, 756-765
Full Text325
Khosla, Sundeep, . (2009) Increasing Options for the Treatment of Osteoporosis. New England Journal of Medicine 361:8, 818-820
Full Text326
Tuan V Nguyen. (2009) Interpretation of randomized controlled trials of fracture prevention. IBMS BoneKEy 6:8, 279-294
CrossRef327
J. E. M. Brouwers, M. Ruchelsman, B. v. Rietbergen, M. L. Bouxsein. (2009) Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats. Osteoporosis International 20:8, 1377-1384
CrossRef328
Jeroen P. Jansen, Gert J. D. Bergman, Jasper Huels, Melvin Olson. (2009) Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Current Medical Research and Opinion 25:8, 1861-1868
CrossRef329
Mark S. Nanes, Caleb B. Kallen. (2009) Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. Fertility and Sterility 92:2, 403-412
CrossRef330
U. Ayazpoor. (2009) Erstes Ortho-Trauma-Update-Seminar. Der Unfallchirurg 112:8, 749-752
CrossRef331
E. Lespessailles, C. Jaffré, H. Beaupied, P. Nanyan, E. Dolléans, C. L. Benhamou, D. Courteix. (2009) Does Exercise Modify the Effects of Zoledronic Acid on Bone Mass, Microarchitecture, Biomechanics, and Turnover in Ovariectomized Rats?. Calcified Tissue International 85:2, 146-157
CrossRef332
T. Matsumoto, H. Hagino, M. Shiraki, M. Fukunaga, T. Nakano, K. Takaoka, H. Morii, Y. Ohashi, T. Nakamura. (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporosis International 20:8, 1429-1437
CrossRef333
Julie A Switzer, Susan Jaglal, Earl R Bogoch. (2009) Overcoming Barriers to Osteoporosis Care in Vulnerable Elderly Patients With Hip Fractures. Journal of Orthopaedic Trauma 23:6, 454-459
CrossRef334
Sara Barnato, Stuart M. Sprague. (2009) Advances in renal bone disease: Osteoporosis and chronic kidney disease. Current Rheumatology Reports 11:3, 185-190
CrossRef335
Atul F. Kamath. (2009) Current Controversies in Bisphosphonate Therapy. Orthopedics 32:7, 473-475
CrossRef336
Daniel H Solomon, Laura Rekedal, Suzanne M Cadarette. (2009) Osteoporosis treatments and adverse events. Current Opinion in Rheumatology 21:4, 363-368
CrossRef337
Kurt A. Kennel, Matthew T. Drake. (2009) Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. Mayo Clinic Proceedings 84:7, 632-638
CrossRef338
Peter Lüthje, Ilona Nurmi-Lüthje, Juha-Pekka Kaukonen, Salla Kuurne, Helena Naboulsi, Matti Kataja. (2009) Undertreatment of osteoporosis following hip fracture in the elderly. Archives of Gerontology and Geriatrics 49:1, 153-157
CrossRef339
K. A. Kennel, M. T. Drake. (2009) Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. Mayo Clinic Proceedings 84:7, 632-638
CrossRef340
2009. Bone and Parathyroid Glands. , 317-361.
CrossRef341
Ian Chapman, Hugh Greville, Peter R. Ebeling, Susannah J. King, Tom Kotsimbos, Patricia Nugent, Rosie Player, Duncan J. Topliss, Janet Warner, John W. Wilson. (2009) Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clinical Endocrinology 70:6, 838-846
CrossRef342
Supriya G. Mohile, Karen Mustian, Kathryn Bylow, William Hall, William Dale. (2009) Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology 70:3, 235-255
CrossRef343
R. Civitelli, R. Armamento-Villareal, N. Napoli. (2009) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporosis International 20:6, 843-851
CrossRef344
Sumio Matzno, Tomoko Nishiguchi, Takeshi Akiyoshi, Setsuko Anami, Toshikatsu Nakabayashi, Kenji Matsuyama. (2009) Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts. Journal of Pharmacy and Pharmacology 61:6, 781-788
CrossRef345
Tomoko Tagawa, Arti Hurria, Joanne Mortimer. (2009) Bone health maintenance in survivors of breast and prostate cancer. Aging Health 5:3, 301-311
CrossRef346
Ilona Nurmi-Lüthje, Peter Lüthje, Juha-Pekka Kaukonen, Matti Kataja, Salla Kuurne, Helena Naboulsi, Kalevi Karjalainen. (2009) Post-Fracture Prescribed Calcium and Vitamin D Supplements Alone or, in Females, with Concomitant Anti-Osteoporotic Drugs is Associated with Lower Mortality in Elderly Hip Fracture Patients. Drugs & Aging 26:5, 409-421
CrossRef347
Robert E. Marx. (2009) Reconstruction of Defects Caused by Bisphosphonate-Induced Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery 67:5, 107-119
CrossRef348
Yosuke Shima, Lars Engebretsen, Junji Iwasa, Katsuhiko Kitaoka, Katsuro Tomita. (2009) Use of bisphosphonates for the treatment of stress fractures in athletes. Knee Surgery, Sports Traumatology, Arthroscopy 17:5, 542-550
CrossRef349
Thomas B. Dodson. (2009) Intravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery 67:5, 44-52
CrossRef350
M.A. Karsdal, K. Henriksen, D.J. Leeming, P. Mitchell, K. Duffin, N. Barascuk, L. Klickstein, P. Aggarwal, O. Nemirovskiy, I. Byrjalsen, P. Qvist, A.C. Bay-Jensen, E.B. Dam, S.H. Madsen, C. Christiansen. (2009) Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14:3, 181-202
CrossRef351
, Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer. (2009) Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009. Wiener Medizinische Wochenschrift 159:S122, 1-34
CrossRef352
B. Abrahamsen, P. Eiken, K. Brixen. (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. Journal of Internal Medicine 265:5, 581-592
CrossRef353
Leon A. Assael. (2009) Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies. Journal of Oral and Maxillofacial Surgery 67:5, 35-43
CrossRef354
P. Makras, N.A.T. Hamdy, A.H. Zwinderman, B.E.P.B. Ballieux, S.E. Papapoulos. (2009) Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone 44:5, 766-771
CrossRef355
Salvatore L. Ruggiero, Thomas B. Dodson, Leon A. Assael, Regina Landesberg, Robert E. Marx, Bhoomi Mehrotra. (2009) American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update. Journal of Oral and Maxillofacial Surgery 67:5, 2-12
CrossRef356
Bruno Frediani, Luca Cavalieri, Giovanni Cremonesi. (2009) Clodronic Acid Formulations Available in Europe and their Use in Osteoporosis. Clinical Drug Investigation 29:6, 359-379
CrossRef357
A. Sebba. (2009) Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporosis International 20:5, 675-686
CrossRef358
Regina Ebert, Sabine Zeck, Ralf Krug, Jutta Meissner-Weigl, Doris Schneider, Lothar Seefried, Jochen Eulert, Franz Jakob. (2009) Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44:5, 858-864
CrossRef359
Franck Grados, Jacques Fechtenbaum, Elisabeth Flipon, Sami Kolta, Christian Roux, Patrice Fardellone. (2009) Radiographic methods for evaluating osteoporotic vertebral fractures. Joint Bone Spine 76:3, 241-247
CrossRef360
Charles A. Inderjeeth, Adrian C.H. Foo, Michelle M.Y. Lai, Paul Glendenning. (2009) Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence. Bone 44:5, 744-751
CrossRef361
R. Bartl, R. Gradinger. (2009) Aktuelle Diagnostik und Therapie der Osteoporose auf der Basis der „European Guidance 2008“. Der Orthopäde 38:4, 365-380
CrossRef362
Amy H. Warriner, Ryan C. Outman, Kenneth G. Saag, Sarah D. Berry, Cathleen Colón-Emeric, Kellie L. Flood, Kenneth W. Lyles, S Bobo Tanner, Nelson B. Watts, Jeffrey R. Curtis. (2009) Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture. Southern Medical Journal 102:4, 397-404
CrossRef363
Luigi Gennari, John P Bilezikian. (2009) Glucocorticoid-induced osteoporosis: hope on the HORIZON. The Lancet 373:9671, 1225-1226
CrossRef364
E. Michael Lewiecki, Sanford Baim, John P. Bilezikian, Richard Eastell, Meryl S. LeBoff, Paul D. Miller. (2009) 2008 Santa Fe Bone Symposium: Update on Osteoporosis. Journal of Clinical Densitometry 12:2, 135-157
CrossRef365
David M Reid, Jean-Pierre Devogelaer, Kenneth Saag, Christian Roux, Chak-Sing Lau, Jean-Yves Reginster, Philemon Papanastasiou, Alberto Ferreira, Florian Hartl, Taiwo Fashola, Peter Mesenbrink, Philip N Sambrook. (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. The Lancet 373:9671, 1253-1263
CrossRef366
Wenjun Li, John Kornak, Tamara Harris, Joyce Keyak, Caixia Li, Ying Lu, Xiaoguang Cheng, Thomas Lang. (2009) Identify fracture-critical regions inside the proximal femur using statistical parametric mapping. Bone 44:4, 596-602
CrossRef367
T. Jared Bunch, Jeffrey L. Anderson, Heidi T. May, Joseph B. Muhlestein, Benjamin D. Horne, Brian G. Crandall, J. Peter Weiss, Donald L. Lappé, Jeffrey S. Osborn, John D. Day. (2009) Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation. The American Journal of Cardiology 103:6, 824-828
CrossRef368
S. Casari, L. Sinigaglia. (2009) L’aderenza alle terapie per l’osteoporosi: l’esempio dei bisfosfonati. Archivio di Ortopedia e Reumatologia 119:3-4, 28-30
CrossRef369
Paul D. Miller. (2009) Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease. Seminars in Nephrology 29:2, 144-155
CrossRef370
Jason M Hollander, Jeffrey I Mechanick. (2009) Bisphosphonates and metabolic bone disease in the ICU. Current Opinion in Clinical Nutrition and Metabolic Care 12:2, 190-195
CrossRef371
Stuart L. Silverman. (2009) Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture. Current Osteoporosis Reports 7:1, 1-2
CrossRef372
Robert W. Lash, Jane M. Nicholson, Lourdes Velez, R. Van Harrison, Jane McCort. (2009) Diagnosis and Management of Osteoporosis. Primary Care: Clinics in Office Practice 36:1, 181-198
CrossRef373
Anthony I. Sebba, Ronald D. Emkey, Joseph D. Kohles, Philip N. Sambrook. (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis. Bone 44:3, 423-427
CrossRef374
Brendon Stubbs, Enrique Zapata-Bravo, Camilla Haw. (2009) Screening for osteoporosis: a survey of older psychiatric inpatients at a tertiary referral centre. International Psychogeriatrics 21:01, 180
CrossRef375
Ali Zamani, Gholamhossein R. Omrani, Masoud Mousavi Nasab. (2009) Lithium's effect on bone mineral density. Bone 44:2, 331-334
CrossRef376
Mohammad Arabmotlagh, Mathias Pilz, Jörg Warzecha, Michael Rauschmann. (2009) Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. Journal of Orthopaedic Research 27:2, 183-188
CrossRef377
M. Sosa Henríquez, D. Hernández Hernández. (2009) Tratamiento de las osteoporosis. Revista Clínica Española 209, 41-47
CrossRef378
Tobias Johannes de Villiers. (2009) Bone health and osteoporosis in postmenopausal women. Best Practice & Research Clinical Obstetrics & Gynaecology 23:1, 73-85
CrossRef379
Robert E Coleman. (2009) Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer. Nature Clinical Practice Endocrinology & Metabolism 5:2, 72-73
CrossRef380
B.C.J.M. Fauser, B.M.J.L. Mannaerts, P. Devroey, A. Leader, I. Boime, D.T. Baird. (2009) Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Human Reproduction Update 15:3, 309-321
CrossRef381
Johann D. Ringe, Patrice Fardellone, Hans-Peter Kruse, Michael Amling, Stefan A.P. van der Geest, Gerd Möller. (2009) Value of a New Fixed-Combination Pack of Bisphosphonate, Calcium and Vitamin D in the Therapy of Osteoporosis. Drugs & Aging 26:3, 241-253
CrossRef382
O. Ström, F. Borgström, J. A. Kanis, B. Jönsson. (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporosis International 20:1, 23-34
CrossRef383
Adrianne C. Feldstein, Derek Weycker, Gregory A. Nichols, Gerry Oster, Gabriela Rosales, David L. Boardman, Nancy Perrin. (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:1, 153-159
CrossRef384
Jacques P Brown, Richard L Prince, Chad Deal, Robert R Recker, Douglas P Kiel, Luiz H de Gregorio, Peyman Hadji, Lorenz C Hofbauer, Jose M Álvaro-Gracia, Huei Wang, Matthew Austin, Rachel B Wagman, Richard Newmark, Cesar Libanati, Javier San Martin, Henry G Bone. (2009) Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research 24:1, 153-161
CrossRef385
Steven Lehrer, André Montazem, Lakshmi Ramanathan, Melissa Pessin-Minsley, John Pfail, Richard G. Stock, Rita Kogan. (2009) Bisphosphonate-Induced Osteonecrosis of the Jaws, Bone Markers, and a Hypothesized Candidate Gene. Journal of Oral and Maxillofacial Surgery 67:1, 159-161
CrossRef386
Yoon Kong Loke, Vinodh Jeevanantham, Sonal Singh. (2009) Bisphosphonates and Atrial Fibrillation. Drug Safety 32:3, 219-228
CrossRef387
S. Rietbrock, M. Olson, T.P. van Staa. (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102:1, 35-42
CrossRef388
Peyman Hadji. (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critical Reviews in Oncology/Hematology 69:1, 73-82
CrossRef389
, , , . (2009) Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ) - Position Statement of Korea -. Journal of Korean Endocrine Society 24:4, 227
CrossRef390
Jung-Chul Park, Ui-Won Jung, Chang-Sung Kim, Kyoo-Sung Cho, Jung-Kiu Chai, Chong-Kwan Kim, Seong-Ho Choi. (2009) Mechanism, prevention, risk assessment and treatment in bisphosphonates induced osteonecrosis of the jaw. The Journal of the Korean Academy of Periodontology 39:1, 1
CrossRef391
M. Sosa Henríquez, M.J. Gómez de Tejada Romero. (2009) La medicina basada en la evidencia y los fármacos aprobados para el tratamiento de la osteoporosis. Papel del calcio y la vitamina D. Revista Clínica Española 209:1, 25-36
CrossRef392
Michael T. McDermott. 2009. Osteoporosis. , 89-98.
CrossRef393
Jeannie Huang, Linda Meixner, Susan Fernandez, J Allen McCutchan. (2009) A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23:1, 51-57
CrossRef394
Ian R. Reid. (2009) Osteonecrosis of the jaw — Who gets it, and why?. Bone 44:1, 4-10
CrossRef395
Anthony Sebba. (2008) Osteoporosis: how long should we treat?. Current Opinion in Endocrinology, Diabetes and Obesity 15:6, 502-507
CrossRef396
Eva Yuet-wah CHU, Shirley Wan-yin TSANG, Annie Wai-chee KUNG. (2008) Treatment options for postmenopausal osteoporosis in Asia. International Journal of Rheumatic Diseases 11:4, 386-392
CrossRef397
Mark A Perazella, Glen S Markowitz. (2008) Bisphosphonate nephrotoxicity. Kidney International 74:11, 1385-1393
CrossRef398
Seth M Arum. (2008) New developments surrounding the safety of bisphosphonates. Current Opinion in Endocrinology, Diabetes and Obesity 15:6, 508-513
CrossRef399
Tuan V. NGUYEN. (2008) Mapping translational research into individualized prognosis of fracture risk. International Journal of Rheumatic Diseases 11:4, 347-358
CrossRef400
K. Poole, . (2008) Comment on: Hypovitaminosis D among rheumatology outpatients in clinical practice: reply. Rheumatology 48:2, 204-204
CrossRef401
Cathleen S Colón-Emeric. (2008) Fracture prevention in frail older adults: Why, when and how. IBMS BoneKEy 5:11, 426-435
CrossRef402
Silvano Adami, Davide Gatti, Francesco Bertoldo, Leonardo Sartori, Ombretta Munno, Paolo Filipponi, Claudio Marcocci, Bruno Frediani, Ernesto Palummeri, Carmelo Erio Fiore, Daniele Costi, Maurizio Rossini. (2008) Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density. Calcified Tissue International 83:5, 301-307
CrossRef403
Makoto Tanaka, Hiroshi Mori, Ryoji Kayasuga, Yasuo Ochi, Naoki Kawada, Hiroyuki Yamada, Katsuya Kishikawa. (2008) Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 43:5, 894-900
CrossRef404
Pete Anderson, Lisa Kopp, Nicholas Anderson, Kathleen Cornelius, Cynthia Herzog, Dennis Hughes, Winston Huh. (2008) Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opinion on Investigational Drugs 17:11, 1703-1715
CrossRef405
Philip S. Mehler, Allison L. Sabel, Tureka Watson, Arnold E. Andersen. (2008) High risk of osteoporosis in male patients with eating disorders. International Journal of Eating Disorders 41:7, 666-672
CrossRef406
Hiroshi Mori, Makoto Tanaka, Ryoji Kayasuga, Taisei Masuda, Yasuo Ochi, Hiroyuki Yamada, Katsuya Kishikawa, Masako Ito, Toshitaka Nakamura. (2008) Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 43:5, 840-848
CrossRef407
E Michael Lewiecki. (2008) Zoledronic acid in the management of osteoporosis: the HORIZON trials. Therapy 5:6, 829-835
CrossRef408
Ian R. Reid. (2008) Anti-resorptive therapies for osteoporosis. Seminars in Cell & Developmental Biology 19:5, 473-478
CrossRef409
R. Eastell. (2008) Bone turnover markers: An appreciation of the contribution of Dr. P.D. Delmas. Bone 43:4, 649-652
CrossRef410
C. Kasperk, G. Nöldge, P. Meeder, P. Nawroth, F.X. Huber. (2008) Kyphoplastie. Der Chirurg 79:10, 944-955
CrossRef411
E. M. Lewiecki, N. B. Watts. (2008) Assessing response to osteoporosis therapy. Osteoporosis International 19:10, 1363-1368
CrossRef412
Michelle M. McDonald, Sukhdeep Dulai, Craig Godfrey, Negin Amanat, Tamara Sztynda, David G. Little. (2008) Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43:4, 653-662
CrossRef413
S. Boonen, D. Vanderschueren, K. Venken, K. Milisen, M. Delforge, P. Haentjens. (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. Journal of Internal Medicine 264:4, 315-332
CrossRef414
C. Kasperk, G. Nöldge, I. Grafe, P. Meeder, F. Huber, P. Nawroth. (2008) Indikationen und Ergebnisse der Kypho- und Vertebroplastie. Der Internist 49:10, 1206-1218
CrossRef415
Paul D. Miller. (2008) Anti-resorptives in the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 849-868
CrossRef416
E. Michael Lewiecki. (2008) A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis. Journal of Clinical Densitometry 11:4, 478-484
CrossRef417
Arlene M Gallagher, Stephan Rietbrock, Melvin Olson, Tjeerd P van Staa. (2008) Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates. Journal of Bone and Mineral Research 23:10, 1569-1575
CrossRef418
O. Bruyere, M.-L. Brandi, N. Burlet, N. Harvey, G. Lyritis, H. Minne, S. Boonen, J.-Y. Reginster, R. Rizzoli, K. Akesson. (2008) Post-fracture management of patients with hip fracture: a perspective*. Current Medical Research and Opinion 24:10, 2841-2851
CrossRef419
Audrey Neuprez, Jean-Yves Reginster. (2008) Bone-forming agents in the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 869-883
CrossRef420
Socrates E. Papapoulos. (2008) Bisphosphonates: how do they work?. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 831-847
CrossRef421
A.E. Kearns, D.F. Kallmes. (2008) Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement. American Journal of Neuroradiology 29:10, 1816-1822
CrossRef422
R. Bartl. (2008) Therapie der Osteoporose nach der „European Guidance 2008“. Der Internist 49:9, 1126-1136
CrossRef423
Matthew T. Drake, Bart L. Clarke, Sundeep Khosla. (2008) Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clinic Proceedings 83:9, 1032-1045
CrossRef424
Julienne E. M. Brouwers, Bert Rietbergen, Mary L. Bouxsein. (2008) Influence of Early and Late Zoledronic Acid Administration on Vertebral Structure and Strength in Ovariectomized Rats. Calcified Tissue International 83:3, 186-191
CrossRef425
Julie T. LI-YU. (2008) Agony of a retired pediatrician. International Journal of Rheumatic Diseases 11:3, 296-302
CrossRef426
B. M. Misof, M. Bodingbauer, P. Roschger, T. Wekerle, B. Pakrah, M. Haas, A. Kainz, R. Oberbauer, F. Mühlbacher, K. Klaushofer. (2008) Short-Term Effects of High-Dose Zoledronic Acid Treatment on Bone Mineralization Density Distribution After Orthotopic Liver Transplantation. Calcified Tissue International 83:3, 167-175
CrossRef427
Steven Boonen, Deborah E Sellmeyer, Kurt Lippuner, Alexander Orlov-Morozov, Ken Abrams, Peter Mesenbrink, Erik F Eriksen, Paul D Miller. (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International 74:5, 641-648
CrossRef428
Barbara J. Messinger-Rapport, David R. Thomas, Julie K. Gammack, John E. Morley. (2008) Clinical Update on Nursing Home Medicine: 2008. Journal of the American Medical Directors Association 9:7, 460-475
CrossRef429
Marie-Hélène Lafage-Proust. (2008) Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women. Kidney International 74:5, 557-559
CrossRef430
Marc C. Hochberg. (2008) Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. Current Osteoporosis Reports 6:3, 89-94
CrossRef431
Falk Hoffmann, Tatjana I. Jung, Dieter Felsenberg, Gerd Glaeske. (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiology and Drug Safety 17:9, 896-903
CrossRef432
Michael T Yin, Elizabeth Shane, Kathryn Anastos. (2008) Clinical significance of HIV-associated bone loss: when and how to intervene. Future HIV Therapy 2:5, 465-478
CrossRef433
Earl R Bogoch, Victoria Elliot-Gibson, Benjamin G Escott, Dorcas E Beaton. (2008) The Osteoporosis Needs of Patients With Wrist Fracture. Journal of Orthopaedic Trauma 22, S73-S78
CrossRef434
Michel Laroche. (2008) Treatment of Osteoporosis: All the Questions We Still Cannot Answer. The American Journal of Medicine 121:9, 744-747
CrossRef435
Socrates Papapoulos, Polyzois Makras. (2008) Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nature Clinical Practice Endocrinology & Metabolism 4:9, 514-523
CrossRef436
Jane A Cauley, Lisa Palermo, Molly Vogt, Kristine E Ensrud, Susan Ewing, Marc Hochberg, Michael C Nevitt, Dennis M Black. (2008) Prevalent Vertebral Fractures in Black Women and White Women. Journal of Bone and Mineral Research 23:9, 1458-1467
CrossRef437
W P Olszynski. (2008) Role of screening in managing osteoporosis in men. Aging Health 4:4, 329-331
CrossRef438
Mark G. Martens, Howard Shaw. (2008) Maximizing Effectiveness of Bisphosphonate Therapy for Osteoporosis. Southern Medical Journal 101:8, 824-830
CrossRef439
Maria-Theresa Krauth, Alexander Fügl, Reinhard Gruber. (2008) Bisphosphonat-assoziierte Osteonekrosen des Kieferknochens. Wiener klinische Wochenschrift 120:15-16, 467-476
CrossRef440
Ankur A Karnik, Joan M von Feldt. (2008) Osteoporosis in the elderly. Aging Health 4:4, 351-363
CrossRef441
Mark J Bolland, Andrew B Grey, Anne M Horne, Simon E Briggs, Mark G Thomas, Rod B Ellis-Pegler, Karen E Callon, Greg D Gamble, Ian R Reid. (2008) Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. Journal of Bone and Mineral Research 23:8, 1304-1308
CrossRef442
Mary L Bouxsein, Pierre D Delmas. (2008) Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective. Journal of Bone and Mineral Research 23:8, 1155-1167
CrossRef443
Xin Li, Laurie K McCauley. (2008) Osteonecrosis of the jaw: Meeting report from skeletal complications of malignancy V. IBMS BoneKEy 5:8, 289-293
CrossRef444
&NA;. (2008) Adverse-effect profiles of bisphosphonates are largely determined by their route of administration. Drugs & Therapy Perspectives 24:7, 23-26
CrossRef445
(2008) Thigh Pain After Total Hip Replacement. Orthopedics 31:7, 700-701
CrossRef446
Sunil J Wimalawansa. (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opinion on Drug Safety 7:4, 491-512
CrossRef447
Julie Blouin, Alice Dragomir, Yola Moride, Louis-Georges Ste-Marie, Julio Cesar Fernandes, Sylvie Perreault. (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. British Journal of Clinical Pharmacology 66:1, 117-127
CrossRef448
PATRICIA O'MALLEY. (2008) A Once-a-Year Intravenous Treatment of Osteoporosis in Postmenopausal Women. Clinical Nurse Specialist 22:4, 169-171
CrossRef449
Nicole K. Johnson, Timothy Clifford, Kelly M. Smith. (2008) Understanding Risk Factors, Screening, and Treatment of Postmenopausal Osteoporosis. Orthopedics 31:7, 676-680
CrossRef450
R E Coleman. (2008) Risks and benefits of bisphosphonates. British Journal of Cancer 98:11, 1736-1740
CrossRef451
R. G. G. Russell, N. B. Watts, F. H. Ebetino, M. J. Rogers. (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 19:6, 733-759
CrossRef452
Peter Vestergaard. (2008) Adverse Effects of Drugs on Bone and Calcium Metabolism/Physiology. Clinical Reviews in Bone and Mineral Metabolism 6:1-2, 1-16
CrossRef453
Sara Massironi, Fabio Massimo Ulivieri, Daniele Marchelli, Guido Basilisco. (2008) Reduced Bone Mineral Density in Chronic Intestinal Idiopathic Pseudo-Obstruction. The American Journal of Gastroenterology 103:6, 1579-1581
CrossRef454
E. Michael Lewiecki. (2008) Prevention and Treatment of Postmenopausal Osteoporosis. Obstetrics and Gynecology Clinics of North America 35:2, 301-315
CrossRef455
R. Bartl, C. Bartl, R. Gradinger. (2008) Einsatz der Bisphosphonate in der Orthopädie und Unfallchirurgie. Der Orthopäde 37:6, 595-614
CrossRef456
Andrea J. Singer, Steven Boonen. (2008) Osteoporosis management: translating research into optimal fracture protection II. Current Medical Research and Opinion 24:6, 1789-1796
CrossRef457
Aliya Khan. (2008) Osteonecrosis of the jaw – relationship to bisphosphonate use: commentary and perspective. Aging Health 4:3, 217-219
CrossRef458
Lisa M. Hess, Joanne M. Jeter, Marge Benham-Hutchins, David S. Alberts. (2008) Factors Associated with Osteonecrosis of the Jaw among Bisphosphonate Users. The American Journal of Medicine 121:6, 475-483.e3
CrossRef459
M. Pazianas, W. A. Blumentals, P. D. Miller. (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporosis International 19:6, 773-779
CrossRef460
Matthew Andersen, Subhash Kukreja. (2008) Bisphosphonates and Chronic Kidney Disease. Kidney 17:3, 119-121
CrossRef461
J. J. Brown, L. Ramalingam, M. R. Zacharin. (2008) Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?. Clinical Endocrinology 68:6, 863-867
CrossRef462
Gustavo Duque, Bruce R. Troen. (2008) Understanding the Mechanisms of Senile Osteoporosis: New Facts for a Major Geriatric Syndrome. Journal of the American Geriatrics Society 56:5, 935-941
CrossRef463
Ronald D Emkey. (2008) Quarterly intravenous ibandronate for postmenopausal osteoporosis. Women's Health 4:3, 219-228
CrossRef464
Roland D Chapurlat. (2008) Single annual injectable treatment for postmenopausal osteoporosis. Expert Opinion on Drug Delivery 5:5, 583-591
CrossRef465
Piet P Geusens, Christian H Roux, David M Reid, Willem F Lems, Silvano Adami, Jonathan D Adachi, Philip N Sambrook, Kenneth G Saag, Nancy E Lane, Marc C Hochberg. (2008) Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective. Nature Clinical Practice Rheumatology 4:5, 240-248
CrossRef466
Allen E. Goodship, Gordon W. Blunn, Jonathan Green, Melanie J. Coathup. (2008) Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. Journal of Orthopaedic Research 26:5, 693-703
CrossRef467
Amber E King, Elena M Umland. (2008) Osteonecrosis of the Jaw in Patients Receiving Intravenous or Oral Bisphosphonates. Pharmacotherapy 28:5, 667-677
CrossRef468
&NA;. (2008) A Once-Yearly IV Bisphosphonate for Osteoporosis. Obstetrics & Gynecology 111:5, 1208-1209
CrossRef469
Ian R Reid. (2008) Once-yearly zoledronate—an effective preventative therapy for new fractures after hip fracture?. Nature Clinical Practice Endocrinology & Metabolism
CrossRef470
Adam M Brufsky. (2008) Zoledronic acid for cancer therapy-induced and postmenopausal bone loss. Expert Opinion on Pharmacotherapy 9:6, 1013-1028
CrossRef471
Philip N. Sambrook, Peter Ebeling. (2008) Osteonecrosis of the jaw. Current Rheumatology Reports 10:2, 97-101
CrossRef472
, J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International 19:4, 399-428
CrossRef473
E. Michael Lewiecki, John P. Bilezikian, Cyrus Cooper, Marc C. Hochberg, Marjorie M. Luckey, Michael Maricic, Paul D. Miller. (2008) Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3–4, 2007. Journal of Clinical Densitometry 11:2, 313-324
CrossRef474
John H. Wessel, Thomas B. Dodson, Athanasios I. Zavras. (2008) Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study. Journal of Oral and Maxillofacial Surgery 66:4, 625-631
CrossRef475
Alessandro Gozzetti, Luigi Gennari, Daniela Merlotti, Stefania Salvadori, Vincenzo Paola, Annalisa Avanzati, Beatrice Franci, Elena Marchini, Monica Tozzi, Maria Stella Campagna, Ranuccio Nuti, Francesco Lauria, Giuseppe Martini. (2008) The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients. Calcified Tissue International 82:4, 258-262
CrossRef476
Jürg A Gasser, Peter Ingold, Andrea Venturiere, Victor Shen, Jonathan R Green. (2008) Long-Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat. Journal of Bone and Mineral Research 23:4, 544-551
CrossRef477
Pierre D. Delmas. (2008) Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases. Journal of Clinical Densitometry 11:2, 325-338
CrossRef478
H. Blain. (2008) Faut-il dépister l’ostéoporose du sujet âgé ?. La Revue de Médecine Interne 29:4, 269-270
CrossRef479
David G. Pendrys, Stuart L. Silverman. (2008) Osteonecrosis of the jaws and bisphosphonates. Current Osteoporosis Reports 6:1, 31-38
CrossRef480
Sheila A Doggrell. (2008) New horizons for zoledronic acid: results of the HORIZON trials in postmenopausal women with osteoporosis and after hip fracture. Expert Opinion on Pharmacotherapy 9:4, 663-668
CrossRef481
Juliet E Compston. (2008) Zoledronic acid – does it have anabolic as well as anti-resorptive effects?. IBMS BoneKEy 5:3, 103-107
CrossRef482
Nigel J. Bundred, Ian D. Campbell, Neville Davidson, Richard H. DeBoer, Holger Eidtmann, Alain Monnier, Patrick Neven, Gunter von Minckwitz, Joel C. Miller, Nora L. Schenk, Robert E. Coleman. (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer 112:5, 1001-1010
CrossRef483
E. Michael Lewiecki. (2008) Intravenous zoledronic acid for the treatment of osteoporosis. Current Osteoporosis Reports 6:1, 17-23
CrossRef484
Abby Abelson. (2008) A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Current Medical Research and Opinion 24:3, 695-705
CrossRef485
(2008) Zoledronate, Fractures, and Mortality after Hip Fracture. New England Journal of Medicine 358:9, 967-969
Full Text486
Sengen Sun. (2008) Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. Expert Opinion on Therapeutic Targets 12:2, 239-251
CrossRef487
Ian R Reid. (2008) Pathogenesis of osteonecrosis of the jaw. IBMS BoneKEy 5:2, 69-77
CrossRef488
Celestia S Higano. (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nature Clinical Practice Urology 5:1, 24-34
CrossRef489
Steven T. Harris, William A. Blumentals, Paul D. Miller. (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies*. Current Medical Research and Opinion 24:1, 237-245
CrossRef490
Stefan H Greiner, Britt Wildemann, David A Back, Mahtala Alidoust, Philipp Schwabe, Norbert P Haas, Gerhard Schmidmaier. (2008) Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthopaedica 79:5, 717-725
CrossRef491
S.M. Berney. (2008) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. Yearbook of Medicine 2008, 59-61
CrossRef492
William E. Braun. 2008. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
CrossRef493
Robert E. Coleman, Jean-Jacques Body, Julie R. Gralow, Allan Lipton. (2008) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treatment Reviews 34, S31-S42
CrossRef494
Simon R. Knight, Peter J. Morris. 2008. Azathioprine and Steroids. , 220-233.
CrossRef495
Shubham Pant, Charles L Shapiro. (2008) Aromatase Inhibitor-Associated Bone Loss. Drugs 68:18, 2591-2600
CrossRef496
Peter R Ebeling, David B Burr. (2008) Editorial: Positive Effects of Intravenous Zoledronic Acid on Bone Remodeling and Structure: Are Different Effects on Osteoblast Activity to Other Oral Bisphosphonates Responsible?. Journal of Bone and Mineral Research 23:1, 2-5
CrossRef497
James E Frampton, Caroline M Perry. (2008) Ibandronate. Drugs 68:18, 2683-2707
CrossRef498
Robert R Recker, Pierre D Delmas, Johan Halse, Ian R Reid, Steven Boonen, Pedro A García-Hernandez, Jerzy Supronik, E Michael Lewiecki, Luis Ochoa, Paul Miller, Huilin Hu, Peter Mesenbrink, Florian Hartl, Juerg Gasser, Erik F Eriksen. (2008) Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. Journal of Bone and Mineral Research 23:1, 6-16
CrossRef499
B.L. Clarke. (2008) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. Yearbook of Endocrinology 2008, 212-214
CrossRef500
Paul D. Miller. (2008) Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Current Medical Research and Opinion 24:1, 107-119
CrossRef501
Pierre D. Delmas, Michael R. McClung, José R. Zanchetta, Artur Racewicz, Christian Roux, Claude-Laurent Benhamou, Zulema Man, Rachelle A. Eusebio, John F. Beary, David E. Burgio, Ellen Matzkin, Steven Boonen. (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:1, 36-42
CrossRef502
Alba Erra, Estefanía Moreno, Isabel Rotés. (2008) Atrial Fibrillation and Zolendronic Acid in Paget's Disease. Reumatolog ía Cl ínica (English Edition) 4:4, 166-167
CrossRef503
John T Schousboe. (2008) Cost Effectiveness of Screen-and-Treat Strategies for Low Bone Mineral Density. Applied Health Economics and Health Policy 6:1, 1-18
CrossRef504
René Rizzoli. (2007) Long-term strategy in the management of postmenopausal osteoporosis. Joint Bone Spine 74:6, 540-543
CrossRef505
Jaroslav Blahoš. (2007) Treatment and prevention of osteoporosis. Wiener Medizinische Wochenschrift 157:23-24, 589-592
CrossRef506
Francesco Bertoldo, Daniele Santini, Vincenzo Lo Cascio. (2007) Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nature Clinical Practice Oncology 4:12, 711-721
CrossRef507
Robert A Adler. (2007) Cancer treatment-induced bone loss. Current Opinion in Endocrinology, Diabetes and Obesity 14:6, 442-445
CrossRef508
Adolfo Díez Pérez. (2007) Aspectos terapéuticos de la osteoporosis. Medicina Clínica 129:20, 773-774
CrossRef509
Juliet Compston. (2007) Over-suppression of bone turnover: Does it exist?. Current Osteoporosis Reports 5:4, 179-185
CrossRef510
Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven, . (2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New England Journal of Medicine 357:18, 1799-1809
Full Text511
Jean-Yves Reginster, Nansa Burlet, Pierre Close, Olivier Bruyere. (2007) Injectable bisphosphonates for the treatment of osteoporosis. Women's Health 3:6, 719-723
CrossRef512
Jane E Aubin, Roger Bouillon, Theresa A Guise, Ian R Reid. (2007) Meeting report from the 17th scientific meeting of the international bone and mineral societyJune 24-29, 2007 in Montréal, Québec, Canada. BoneKEy-Osteovision 4:11, 299-313
CrossRef513
E Michael Lewiecki, Paul D Miller. (2007) Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion on Drug Safety 6:6, 663-672
CrossRef514
E. Michael Lewiecki. (2007) Long dosing intervals in the treatment of postmenopausal osteoporosis. Current Medical Research and Opinion 23:11, 2617-2625
CrossRef515
Jean-Pierre Devogelaer, Daniel H Manicourt. (2007) Zoledronic acid for treatment of Paget's disease of bone. Expert Opinion on Pharmacotherapy 8:16, 2863-2869
CrossRef516
R. Bartl, C.J. Thaler. (2007) Leitliniengerechte Diagnostik und Therapie der postmenopausalen Osteoporose. Der Gynäkologe 40:11, 913-923
CrossRef517
J. J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J. P. Devogelaer, S. Goemaere, J. Y. Reginster, S. Rozenberg, J. M. Kaufman. (2007) Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporosis International 18:11, 1439-1450
CrossRef518
J. Vaile, L. Sullivan, C. Bennett, J. Bleasel. (2007) First Fracture Project: addressing the osteoporosis care gap. Internal Medicine Journal 37:10, 717-720
CrossRef519
Takahiro Hashimoto, Mitsunori Shigetomi, Teruyasu Ohno, Tsunemitsu Matsunaga, Keiichi Muramatsu, Hiroshi Tanaka, Toshihiro Sugiyama, Toshihiko Taguchi. (2007) Sequential Treatment with Intermittent Low-Dose Human Parathyroid Hormone (1-34) and Bisphosphonate Enhances Large-Size Skeletal Reconstruction by Vascularized Bone Transplantation. Calcified Tissue International 81:3, 232-239
CrossRef520
Andrew Grey. (2007) Emerging pharmacologic therapies for osteoporosis. Expert Opinion on Emerging Drugs 12:3, 493-508
CrossRef521
Juliet Compston. (2007) Parathyroid hormone (1–84): new clinical perspectives for treating patients at high-risk of fractures. Expert Review of Obstetrics & Gynecology 2:5, 577-585
CrossRef522
Michelle M McDonald, Aaron Schindeler, David G Little. (2007) Bisphosphonate treatment and fracture repair. BoneKEy-Osteovision 4:9, 236-251
CrossRef523
Ann Cranney, Jonathan D. Adachi. (2007) Bisphosphonates for the Treatment of Postmenopausal Osteoporosis: An Update. Clinical Reviews in Bone and Mineral Metabolism 5:3, 145-152
CrossRef524
(2007) Yearly Zoledronic Acid in Postmenopausal Osteoporosis. New England Journal of Medicine 357:7, 711-715
Full Text525
Jacyntha A. Sterling. (2007) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 42:7, 657-660
CrossRef526
Compston, Juliet, . (2007) Treatments for Osteoporosis — Looking beyond the HORIZON. New England Journal of Medicine 356:18, 1878-1880
Full Text527
Cummings, Steven R., , Schwartz, Ann V., Black, Dennis M., . (2007) Alendronate and Atrial Fibrillation. New England Journal of Medicine 356:18, 1895-1896
Full Text528
Serge Ferrari, Ego Seeman, Gordon J Strewler. (2007) Clinical and basic research papers – April 2007 selections. BoneKEy-Osteovision 4:5, 144-146
CrossRef
- Letters
